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From the 
It President 
Research is to see what 
everybody else has seen, 
and to think what nobody else has thought. 
- Albert Szent-Gyorgyi 
• • • • • 
Medicare Payments 
As we read about the failure of Congress to avert the 
scheduled 5.4% cut in 2002 Medicare physician 
reimbursements, despite bipartisan support, one concludes 
that physicians are being "used" to control Medicare spending. 
Warren Jones, MD, president of the American Academy of FP, 
confirmed that across the board 2002 payment cuts would 
have "immediate negative consequences" on access to patient 
care. He points out that physicians are facing rising practice 
costs, soaring liability insurance premiums, and burdensome 
regulatory loads. 
We remain optimistic that Congress will act to reverse this ill-
considered cut in Medicare payments. 
• • • • • 
I don't even like money; it just quiets my nerves. 
-Bob Hope 
• • • • • 
Medical Manpower 
December's Pro Tempore carried a report about the growing 
shortage of physicians in southeastern Pennsylvania. The 
newswire item below confirms that the issue is real. It is also 
consistent with the numerous stories in the last year about the 
"vanishing healthcare worker. • We are aware of the shortage 
of nurses, pharmacists, skilled health aids, technologists, 
physical therapists, radiology techs, etc. The "service 
professions" are being stretched and stressed. We need to 
understand the forces shaping our society while we value and 
support each other as healthcare team members. 
The U.S. will soon be facing a shortage of physicians that 
will become progressively more severe, leading to a 
deficit of 200,000 physicians by 2020, according to a study 
in Health Affairs. 
(Continued on Page 2) 
(Continued from Page 1) 
Using a newly developed physician supply trend model, 
researchers said the data debunk predictions over the past 20 
years that there would be a 15 to 30 percent surplus of 
specialty physicians by 2000, reported AMNews. Researchers 
said previous studies had failed to accurately account for 
population growth, work-effort of physicians, contribution of 
services by non-physicians and economic expansion, AMNews 
added. (Health Affairs, January/February, 2002; American 
Medical News, January 21, 2002) 
• • • • • 
Bons mots 
I'm living so far beyond my income that we may be said to be 
living apart. 
- E. E. Cummings 
• • • • • 
Malpractice Crisis 
Gov. Schweiker called on the State Legislature to put 
"Strong Reforms" of PA's Medical Malpractice System at 
the top of its agenda for January. 
Schweiker gave no details, but he said the legislature should 
address patient-safety issues as well as legal reforms, 
reported the Philadelphia Inquirer. 
LVHHN has continued to emphasize patient safety initiatives in 
every aspect of patient care, and we understand that this is our 
first priority. A comprehensive program (called Primum Non 
Nocere) with multiple safety projects is underway with periodic 
reports to Senior Management Council. Progress is being 
made on a number of fronts. 
Let us all think clearly about the essential elements of the 
malpractice situation. 
There are two separate questions here: 
1. Do medical errors occur (yes) and are patients injured 
as a result? (unfortunately, yes again). 
2. What is the best system to reduce errors and protect 
our patients? 
Any impartial observer would conclude that the present tort 
system has FAILED to reduce errors and compensate fairly 
those patients injured by medical errors. (Less than one in 
eight patients so injured is compensated.) In addition, the 
COST has gotten out of control (about 60% of premium dollars 
goes to our legal colleagues). As significant monetary 
beneficiaries of the present tort system, the Pennsylvania Trial 
Lawyers Association will find it impossible to be impartial in 
these discussions. Our legislators should understand this. We 
certainly do. 
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An alternative system that has worked in California for 26 
years is a variation of workers' compensation no-fault system. 
Countries in Scandinavia have a no-fault patient compensation 
insurance system. Screening panels and arbitration are also 
alternatives. 
The medical staff enthusiastically supports medical 
accountability and responsibility in patient safety efforts, which 
require blame-free reporting of all medical errors and the 
system changes to prevent such errors in the future. The 
present tort system not only is NOT helping in this effort; it has 
become an obstacle. In a way, the tort system is contributing 
to continued patient injuries. 
• • • • • 
Nothing great was ever achieved without enthusiasm. 
-Ralph Waldo Emerson (Circles) 
• • • • • 
A swift first step in the struggle might be to reinstate the 
malpractice legislation previously passed by the Legislature in 
1997 and struck down by the PA Supreme Court ... 
Pennsylvania Attorney General Mike Fisher today sent a 
letter to Chief Justice Stephen A. Zappala of the 
Pennsylvania Supreme Court asking that the Court take 
steps to alleviate the high costs of medical malpractice 
insurance. 
In January 1997, the Supreme Court suspended several key 
provisions of the Health Care Services Malpractice Act, saying 
it interfered with the court's rulemaking authority. The court 
then ordered its Civil Procedural Rules Committee to 
recommend changes to cover the 
issues. However, no recommendations have been made. " ... 1 
would urge the court to consider reversing the suspension of 
the provisions of Act 135." (Pennsylvania Office of Attorney 
General, January 7, 2002) 
• • • • • 
A rich man is nothing but a poor man with money. 
- W.C. Fields 
• • • • • 
Nursing at LVHHN - The Draw of the Magnet 
At LVHHN, our nursing turnover rate has dropped from 16.5% 
to 10%. Our vacancy rate is 7-10% - the lowest in years -
compared with national vacancy rates of 20%. We strive to 
provide more individualized caring with ratios that exceed other 
local hospitals and are excellent compared with national 
averages. 
(Continued on Page 3} 
· (Continued from Page 2) 
At LVHHN, nurses have: a voice in decision making, active 
role in nursing improvements, flexible schedules, 
compensation incentives, scholarships, tiered float pool, 
educational and professional development, succession 
planning, endowed chair in nursing, three Nightingale of 
Pennsylvania award finalists, and increased communications 
with physicians. 
• • • • • 
Let us not look back in anger or forward on fear, but around in 
awareness. 
- James Thurber 
• • • • • 
PHO Update 
With some recent contract signings by Mr. Greg Kile, Valley 
Preferred (our wholly owned PPO) has become one of the 
largest PPO's in Pennsylvania with 80,000 enrollment. The 
PHO has enthusiastically supported the CAPOE project and 
receives regular progress reports from Dr. Don Levick. The 
hospital and the PHO (represented by Dr. John Jaffe) jointly 
run the Care Management Council, which oversees LOS 
issues among others. With the help of Dr. Paula Stillman and 
medical staff members, successful efforts are underway to 
reduce the LOS creep. We ask your help in this effort to 
maximize our capacity and our ability to care for our 
community. 
• • • • • 
Golfer: "This golf is a funny game." 
Caddy: "It's not supposed to be." 
• • • • • 
Time may be a great healer, but it's also a lousy beautician. 
Edward M. Mullin, Jr., MD 
Medical Staff President 
Attention: PalmPilot Users 
The LVHHN Medical Staff Directory, a listing of 
the LVHHN Residents, and the LVHHN 
Telephone Hotlist are now available through the 
Medical Staff Services Office. If you have a Palm 
Ill, Palm V, Palm M505, or a HandSpring, the 
above information can be hot synced to your 
PalmPilot. For more information or to schedule a 
convenient time to stop by, please contact Beth 
Martin in Medical Staff Services at (610) 402-8980. 
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Spotlight on ... 
David P. Carney, MD 
Dr. Carney is originally from State 
College, Pa. He completed his 
undergraduate education at the 
Pennsylvania State University where he earned a Bachelor of 
Science degree. He received his medical degree from 
Hahnemann Medical College of Philadelphia. He completed a 
rotating internship and medical residency at the Allentown 
Affiliated Hospitals, and went on to serve as the first Chief 
Medical Resident of that program. 
Dr. Carney is certified in both Internal Medicine and Geriatric 
Medicine by the American Board of Internal Medicine. 
Dr. Carney joined the hospital's Medical Staff in 1979 and is a 
member of the Department of Medicine, Division of General 
Internal Medicine/Geriatrics. He is currently Associate Chief of 
the Division of Geriatrics, and is the Medical Director of the 
Lehigh Valley Transitional Skilled Unit at 17th & Chew. He is 
also a Clinical Assistant Professor of Medicine at Pennsylvania 
State University College of Medicine. 
On a more personal note, Dr. Carney and his wife, Barbara, 
have three children. In his spare time, Dr. Carney enjoys 
sailing, music, and woodworking. 
In conclusion, Dr. Carney has the following comments to share 
with his colleagues on the Medical Staff: 
"Medicine is a continuum, and we are responsible for 
propagating our profession to those who follow. I'd like to 
share some of the valuable lessons I've learned from those 
who taught me." 
"When the patient talks -listen. He is telling you his 
diagnosis. • "Always try to treat people a little better than they 
may deserve to be treated." - Paul L. Carney, MD 
"Be attentive to detail in clinical examination, lest you miss 
something important." - Stanley E. Zeeman, MD 
"Within medical reason, give patients what they want- the 
customer is always right." - Herbert L. Hyman, MD 
• The core of professionalism is staying consistent and focused 
in dealing with patients. • -Barre D. Kaufman, MD 
"You're never alone in medicine when facing a problem; there's 
a wealth of information waiting to help in the medica/library. • 
-Dean F. Dimick, MD 
L VHHN to Expand Facilities and 
Services at Lehigh Valley Hospital-
Muhlenberg 
To better serve the needs of the growing and aging 
Northampton County community, Lehigh Valley Hospital and 
Health Network (LVHHN) has announced plans for the 
continued expansion and improvement of facilities and 
services at Lehigh Valley Hospital-Muhlenberg (LVH-
Muhlenberg) on Schoenersville Road in Bethlehem. 
A multi-story building will be constructed to house an extension 
of the network's Regional Heart Center and contain 56 beds for 
critical care, cardiac and general medical/surgical patients. 
Work on this pavilion is expected to begin in the fall and be 
completed in June 2004. At its January 9 meeting, the health 
network's board of trustees approved $39 million in funding for 
these facilities and services improvements, of which $13.5 
million ($8.5 million for invasive cardiology; $5 million for 
surgery) is designated for Regional Heart Center expansion. A 
comprehensive open heart surgery program, an integral part of 
LVH's Regional Heart Center, will be launched at LVH-
Muhlenberg in June. 
"This project further demonstrates LVHHN's continuing 
commitment to providing high-quality and easily accessible 
services at L VH-Muhlenberg to meet the health care needs of 
our community in Northampton County and the surrounding 
region," said Elliot J. Sussman, MD, LVHHN's president and 
chief executive officer. 
The Regional Heart Center space will comprise non-surgery 
cardiology diagnostic testing and treatment services-two 
cardiac catheterization/electrophysiology laboratories, and 
patient preparation and recovery areas-and patient care units 
for medical cardiology and recovering open heart surgery 
patients. 
In addition, the building will house an intensive care unit and a 
general medical/surgical unit. The top floor will be reserved for 
future development. The 1 00,000+-square-foot wing will be 
located adjacent to the Children's Hospital of Philadelphia 
Specialty Care Center on the western edge of the campus. 
The new addition's entrance will face north, and it will be 
visible and accessible from Routes 378 and 22 and 
Schoenersville Road. ' 
"The Lehigh Valley Health Network board of trustees has 
studied this carefully for some time now, and we are excited to 
invest further in the future health of the community as we bring 
more services to Lehigh Valley Hospital-Muhlenberg," said 
William Lehr, chairman of the board of LVH-Muhlenberg. 
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Open heart surgery at LVH-Muhlenberg will be performed in a 
specially designed operating room within the hospital's surgical 
suite. During construction of the wing, a second cardiac 
catheterization lab will be built on the hospital's second floor 
adjacent to the current lab. This new lab will be moved to the 
new building upon its completion, where a second new lab will 
be added. 
"These improvements will enhance and expand our ability to 
provide high-quality heart care to any patient who comes to 
this hospital," said cardiologist Anthony Urbano, MD, medical 
director of interventional cardiology at LVH-Muhlenberg. "As a 
Lehigh Valley Hospital and Health Network initiative, this 
project brings to the LVH-Muhlenberg campus the combined 
resources and expertise of a broad range of network 
specialists." 
Dr. Urbano and his colleagues in Lehigh Valley Cardiology 
Associates -- the largest cardiology practice serving 
Northampton County -- recently relocated their practice to a 
larger facility on the LVH-Muhlenberg campus. 
"Cardiovascular disease is the leading cause of death in the 
U.S. and is primarily responsible for about 40 percent of all 
deaths in the Lehigh Valley," said Fernando Garzia, MD, chief 
of cardio-thoracic surgery at LVH-Muhlenberg. "With national 
research predicting an even greater need for cardiology 
services in the future, Lehigh Valley Hospital and Health 
Network's decision to enhance heart services at the 
Muhlenberg campus is an important step in responding to the 
health care needs of Bethlehem and the surrounding 
Northampton County communities. • 
According to Robert J. Laskowski, MD, LVHHN's chief medical 
officer, "We are expanding our 25-year-old nationally 
recognized heart program at Cedar Crest & 1-78 in response to 
patients and physicians in Northampton County who desire 
access to the resources of LVHHN's Regional Heart Center." 
Work began in August to expand and modernize LVH's 
Regional Heart Center located on its Cedar Crest & 1-78 
campus in Allentown. 
The LVHHN Regional Heart Center performs the largest 
volume of interventional and surgical heart care in the region, 
in keeping with its tradition of innovative leadership. The first 
case of open heart surgery in the Lehigh Valley was performed 
at Lehigh Valley Hospital, 17th & Chew (then called Allentown 
Hospital) in 1974. The Regional Heart Center is also a pioneer 
in new technologies, including the use of radiation to prevent 
the ~-closing of vessels after angioplasty, and stenting; 
beat1ng heart surgery; and radio-frequency ablation to cure 
atrial fibrillation, an irregular quivering of the heart, which can 
lead to stroke. Each year, cardiac care teams at LVHHN 
(Continued on Page 5) 
(Continued from Page 4) 
perform 5,000 catheterizations, 1 ,900 angioplasties, 1 ,250 
procedures for electrical problems of the heart, and more than 
1,000 cases of open heart surgery. 
Since the 1997 merger of LVHHN and Muhlenberg Hospital 
Center, the following services and facilities have been added 
at Lehigh Valley Hospital-Muhlenberg: 
•!• The Children's Hospital of Philadelphia Specialty Care 
Center 
•!• The Behavioral Health Science Center 
•!• The Lehigh Valley Hospital Cancer Center 
•!• The region's only advanced technology in-vitro fertilization 
laboratory 
•!• The new ambulatory surgery unit, including the area's only 
ambulatory pediatric surgery facility 
•!• The Sleep Disorders Center 
•!• The Wound Care Center 
•!• The Rehabilitation, Physical Therapy and Sports Medicine 
Center 
•!• A new Breast Health Center 
News from CAPOE Central 
One of the advantages of a CAPOE system is the potential for 
clinical decision support. The CAPOE system is an excellent 
platform to provide physicians with feedback and information 
pertaining to the orders being written. A great example of this 
is the maximum dosing calculation, which has been created 
through a tremendous amount of work by the Pharmacy 
Department. When medications are ordered on-line, the 
system will compare the order against the maximum dose 
(both single dose and total daily dose) based on age. If the 
maximum dose is exceeded, a warning will appear in the 
Status Bar in the lower left comer of the screen. The alert is 
for information only, and the ordering physician or provider can 
still place the order. 
A special"thank you" goes out to Karen Johnston, Mary Beth 
Karoly and Janine Barnaby in the Pharmacy Department for 
their hard work and energy in completing this project. Also, 
many thanks to Jill Green and the rest of the Pharmacy 
Department for their commitment and support The Pharmacy 
identified the maximum dosing project as an important and 
valuable clinical tool, and they worked hard to bring the project 
to completion. 
The success of CAPOE will come as a result of collaborative 
work between all the departments and the desire by the 
physicians and staff to improve patient care. 
Don Levick, MD, MBA 
(484) 884-4593 (office) or (610) 402-5100 7481 (pager) 
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News from the HIM Department 
Histories and Physicals 
5 
Over the past several months, two problems have been 
identified relating to history and physical (H&P} documentation: 
( 1) H&P for elective admissions are done more than 30 days 
prior to the scheduled admission; and (2) Transcription is being 
requested to go back to old dictations and update with new 
dates to meet the 30 day requirements. 
Regulatory agencies require that histories and physicals be 
dictated no more than 30 days prior to admission. History and 
physical documentation not meeting regulatory requirements 
will be returned to the physician. 
Redictations 
Are you looking for a report you dictated and can't find it in IDX 
or PIM? Your first thought is that it must be lost in the dictation 
system. The dictation system has proven to be very reliable in 
ca~turing identifying information and dictations. Before you 
redtctate the report, call the Transcription Department at (61 0) 
402-8364 to verify whether or not the dictated report is in the 
system. If you redictate the report, not only will this cause 
duplicate dictations and work, but it will also have an effect on 
the turnaround time of all dictations. 
If you have any questions regarding these issues, please 
contact Zelda Greene, Director, Health Information 
Management, at (610) 402-8330. 
Coding Tip of the Month 
Non-specific Principal Diagnosis: Identifies 
principal diagnoses codes identified by the 
Medicare Code Editor as Non-Specific diagnosis 
for patients discharged alive that may indicate a 
PRO review. More precise codes should be used 
for the principal diagnosis. 
CAN a more Specific code be assigned? 
PLEASE, remember to specify: Sites, Chronicity, 
and Organisms. 
SITE: which specific topographical site of the 
organ. Especially, important in malignancies and 
other neoplasm. 
Phlebitis -which vein was involved? 
Mls -which site was the infarction? 
CVAs - please specify cause such as embolus, 
thrombus, or stenosis of cerebral artery with 
infarct? 
Information Services News 
Customer Service 
F 
Information Services Customer Service (610-402-8303) is 
covered 24 hours, seven days a week by the 1/S Helpdesk (the 
first level of any 1/S assistance) and the 1/S Call Center (the 
same department that handles the hospital Paging Services). 
Normal Customer Service hours are Monday through Friday, 7 
a.m. to 5:30p.m. During these hours, the department is 
staffed to handle service calls directly to the Helpdesk, with 
overflows going to the Call Center (to obtain the necessary 
information to process calls and refer them to the Helpdesk 
staff). 
During off-shift hours, the Call Center will continue to answer 
calls. Calls will be routed to the Computer Operator Staff for 
assistance. If they can, they will handle the problem. If the 
problem is out of the realm of the operator, and of a serious 
nature, the call will be forwarded to the On Call team. 
Unfortunately, the low volume of calls on the night shift does 
not warrant around the clock Helpdesk service. In the event 
that 1/S is unable to handle your call immediately, they will 
make every effort to get back to you as soon as possible. 
If you have any questions regarding this issue, please contact 
Rob Bortz in 1/S Operations at (610) 402-1481. 
Computer Passwords 
Login passwords change every 90 days in compliance with 
policy and regulatory requirements. When your password 
expires, you will be forced to change it to a new password. 
Your new password must: 
1. Be at least six characters (a-zA-Z) 
2. Contain at least one non-alphabet character (0-9,!@# ... ) 
3. Contain at least one alphabet character 
4. Be different from your user ID and your old password 
How to Make It Easier 
•!• Pick a word and add a sequence to it when it must 
change: 
Security1, Security2, Security3, ... 
•!• Pick a word and substitute symbols for letters: 
r011ca11 (a zero and some one's for the Ls) 
r00tb33r (zero's and three's for the E's) 
$talks (money talks) 
•!• Use a song/poem/phrase to make a password: 
Ride across the river, deep and wide - - - - - -
Ratrdaw 
! Qledge ~llegiance !o !he ~ag 
lpattf 
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Changing Your Password 
Normally when your password expires, you are prompted to 
change your password during the login process. Follow the 
instructions on the screen and the system 'walks' you through 
the process. 
You can also change your password at any time by initiating a 
change. Press Ctri-Ait-Del and select the "Change Password" 
option, then follow the instructions on screen. 
If you have trouble with your account password, please call the 
1/S Helpdesk at (61 0) 402-8303. 
New Anti-Aging Medicine Initiative 
In an effort to meet patient demands for enhancement of their 
well-being and appearance, an Anti-Aging Medicine Program 
has been established for Lehigh Valley Hospital and Health 
Network. The Youthful You Institute at Lehigh Valley 
Hospital-Muhlenberg will offer a comprehensive approach to 
looking and feeling younger. 
According to Robert X. Murphy, Jr., MD, who has been named 
Medical Director for the Anti-Aging Medicine Program, "People 
are excited about opportunities to improve their health and 
appearance. Wellness, health and pampering are now a 
combined experience. n 
The Youthful You Institute at Lehigh Valley Hospital-
Muhlenberg, which will open its doors off the main lobby in 
March, will offer the following services: natural nail care 
services, skin care treatments, massage therapies, 
nutrition/weight management therapies along with personal 
exercise training consults, aesthetic procedures, physician 
consultations, and physician-approved products. The phone 
number for the Youthful You Institute is (484) 884-7045. 
For more information regarding this new program, please 
contact Greg Salem, Program Administrator, at (610) 402-
7000. 
Currently, the secretary for the Diagnostic Care 
Center at Cedar Crest & 1-78 answers the phone 
number - (610) 402-8390 - for the Nuclear 
Medicine Department. Although she is not 
physically located within the Nuclear Medi~ine 
Department, she will direct calls to the appropnate 
person. 
All requests for reports/films should be directed to 
the Radiology File Room at (61 0) 402-8070. This 
includes requests for PET Scans. 
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Community Acquired Pneumonia 
Lehigh Valley Hospital participated in the national KePRO project-- Community Acquired Pneumonia (CAP). This project used five 
quality indicators developed by the Health Care Financing Administration (HCFA) in consultation with content area experts. Data 
obtained during the KePRO re-evaluation period ( 4/1/00 - 12/31 /00) revealed significant improvement in four out of five of these quality 
indicators, as evidenced in the table below: 
BASELINE REMEASUREMENT 
INDICATORS Numerator Denominator* % Numerator Denominator* % 
Initial antibiotics within 8 hours after arrival 21 30 70% 40 44 91% 
Initial antibiotics consistent with current recommendations 19 23 83% 39 42 93% 
Blood cultures collected before antibiotics administered 22 25 88% 35 37 95% 
Patient screened or given influenza vaccination (Oct-Dec) 3 6 50% 11 18 61% 
Patient screened or given pneumococcal vaccination 12 29 41% 16 46 35% 
*The number of cases who qualified for the indicator. Th1s number differs for each indicator because of varying inclusion/exclusion 
criteria. 
However, LVH data from April, July, and October 2001 revealed three of these indicators, as well as Length of Stay (LOS) and Variable 
Cost per Case improvements have not been sustained, as evidenced in the chart below: 
DRG 89 PATIENTS WITH ADMITIING DIAGNOSIS OF PNEUMONIA 
Target Apr-01 Jul-01 Oct-01 
1. Total # of Patients 13 20 23 
2. Total LOS Avg 5.0 4.7 5.3 7.0 
3. Ave Var Cost/Case # $1,900 $1,632 $2,133 $3,529 
4. Median Time 
• Arrival until Antibiotic Ordered Hours 1.2 2.4 2.9 
• Arrival until Antibiotic Administration Hours 3.0 3.0 6.1 4.3 
5. Key Indicators 
• Patients with Antibiotics started within 3 hours of arrival 80% 46% 10% 26% 
• Patients with Antibiotics started within 8 hours of arrival 92% 60% 74% 
• Patients with Blood Cultures drawn before Antibiotic Administration 100% 70% 78% . . . . 
NOTE ·Admitting D1agnos1s of Pneumoma was detenmned by Phys1c1an documentation v1a chart rev1ew . 
The current focus of the Community Acquired Pneumonia (CAP) team is to shorten time until antibiotics are ordered and administered. 
Emergency Department and other physicians admitting patients with pneumonia are encouraged to help improve the quality of care to 
pneumonia patients. 
• Please consider using the CAP pre-printed orders that are available in the Emergency Department and on all inpatient units. 
• KePRO Collaboration Newsletter (3/6/00) reports that the use of standing pre-printed orders has shown up to a 69% 
improvement in some aspects of the quality of care. 
• Please remember to order the initial dose of antibiotic and blood cultures STAT in all pneumonia patients. Blood cultures should 
be obtained prior to administration of antibiotics, if possible. 
• Consider administering the pneumococcal and/or influenza vaccine prior to hospital discharge in the clinically stable patients. The 
CDC recommends the pneumococcal vaccine for patients over 65 and for those with chronic medical conditions. When unsure of 
vaccination status, the CDC recommends administering one dose of vaccine. 
• If you have any questions, please contact Jay H. Kaufman, MD, LVH Physician Leader, KePRO Pneumonia Project, at Pager 
(610) 920-7221 or Marlene Ritter, BS, RRT, at (610) 402-1707. 
Physician Assistance Program 
Success in the work environment depends on everyone's 
contribution. That's why no one can afford to ignore 
depression. 
According to the National Institute of Mental Health (NIMH), 
America faces an epidemic of depression. 
);;> At any given time, one out of 20 workers suffers from this 
disease 
);;> Every year, depression causes 200 million lost days of 
work 
);;> Workplace depression drains $44 billion from the 
economy each year, mostly because of absenteeism and 
lower productivity 
);;> Depressed workers have between 1.5 and 3.2 more short-
term disability days 
However, there is good news. More than 80% of depressed 
people can be treated quickly and effectively. The key is to 
recognize the symptoms of depression early and to receive 
appropriate treatment. Unfortunately, nearly two out of three 
people with depression do not receive the treatment they need. 
The Medical Staff of Lehigh Valley Hospital recognizes that a 
wide range of problems in life can affect a physician's health 
and well being, and, at times, professional performance. 
In fact, studies conducted by the National Institute for 
Occupational Health and Safety report that physicians, along 
with other caregivers, may have a higher than average risk of 
developing debilitating personal problems. 
Since 1993, the Physician Assistance Program has been 
available to help members of the Medical Staff deal with 
personal problems before they affect health, family life, or 
professional effectiveness. 
The Physician Assistance Program is a confidential (and if so 
desired, anonymous), professional counseling and referral 
service available to active members of the Medical Staff of 
Lehigh Valley Hospital and their dependents. 
This service is provided through an agreement with Preferred 
EAP which operates the Lehigh Valley Hospital's Employee 
Assistance Program (EAP) and has been involved with over 
4,000 employees and dependents since 1985. 
The Physician Assistance Program offers physicians and their 
families counseling services for a wide range of personal 
problems -- anything that can tum stress into distress -
including marital or relationship difficulties; depression and 
anxiety; alcohol or drug abuse; family problems, or stress from 
work or personal concerns. 
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Program users can choose from a multi-disciplinary team 
assembled to provide Physician Assistance Program services. 
This team includes: 
);;> Michael W. Kaufmann, MD, Chairperson, Department of 
Psychiatry 
);;> John C. Turoczi, EdD, licensed psychologist and member 
of the Allied Health Professional Staff of Lehigh Valley 
Hospital 
);;> Staff of Preferred EAP including licensed social workers, 
masters level clinicians, and certified addiction counselors. 
To use the Physician Assistance Program during normal 
working hours, telephone the Preferred EAP office at (610) 
433-8550 or 1-800-327-8878, identify yourself ONLY as a 
member of the Lehigh Valley Hospital's Medical Staff (or a 
family member), and ask to speak to the Clinical Manager, 
Robin Chase, or Program Director, Oliver Neith. Please note 
that callers may remain anonymous. 
Ms. Chase, or the Preferred EAP receptionist, will conduct a 
brief telephone interview, offer a choice among the above 
listed provider team members, and advise the caller how to 
arrange an appointment. 
Other professional staff of Preferred EAP are available after 
hours to respond to emergency situations. 
The number of visits will vary with the nature and severity of 
the problem. Up to five visits with Physician Assistance 
Program providers are available to active Medical Staff 
members (and their dependents) at no cost. 
If their is a need for further service or treatment, a referral may 
be made to a private practitioner or community resource, or the 
user may continue with the original Physician Assistance 
Program provider on a self-pay basis. 
For more information, contact Robin Chase or Oliver Neith at 
Preferred EAP at (610) 433-8550, or John W. Hart, Vice 
President, in Medical Staff Services, at (610) 402-8980, or any 
member of TROIKA. 
? ? ? Mystery Medical Staff Member ? ? ? 
? Born in Philadelphia 
? Bachelor of Science degree at Wilkes College 
? Medical degree from Hahnemann Medical College 
of Philadelphia 
? Three-year residency at Cleveland Clinic 
Foundation 
? One-year fellowships at both Brigham & Women's 
Hospital and Hahnemann University Hospital 
? Joined the Medical Staff in 1982 
? Offices on L VH-M campus and on Pond Road 
Give up? Please see Page 11 for the answer. 
· On-Call Policy for Nuclear Medicine 
For your information, following is the on-call policy for the 
Section of Nuclear Medicine at Lehigh Valley Hospital. 
After hours and on weekends and holidays, a nuclear medicine 
technologist and a nuclear medicine physician are on-call for 
emergency cases only. These cases include ventilation 
perfusion lung scans, Gl bleed scans, gallbladder scans to rule 
out acute cholecystitis, nuclear medicine brain death scans, 
and bone scans to rule out osteomyelitis in pediatric patients 
who will be taken to the operating room that same day if the 
scan is positive. In all non-emergent cases or if the scan 
would not change the course of therapy for the patient that 
day, the nuclear medicine study will be performed during the 
next normal working day. 
It is also important for the ordering physician to contact the 
nuclear medicine physician on-call directly for any emergency 
on-call case. This will provide the nuclear medicine physician 
with important clinical information so that the technologist can 
better tailor the study to that particular patient's needs if 
indicated. 
It is felt that this policy will meet the emergency needs of our 
patients and will optimally utilize hospital resources in terms of 
radioisotope purchase and on-call technologists' time. 
If you have any questions or concerns about the nuclear 
medicine on-call policy, please contact Robert J. Rienzo, MD, 
Chief, Section of Nuclear Medicine, at (610) 402-8373. 
LOVARNews 
The LOVAR (Lowering of Vascular Atherosclerotic Risk) Study 
has recently completed recruitment of the 500 patients needed 
for the intervention and control arms of the study. Although 
recruitment of patients is now closed, the LOVAR team will be 
following the 500 participants closely over the next three years. 
The LOVAR team will continue to keep you informed of your 
patient's progress in the study. 
Using the principles and strategies gleaned in LOVAR, the 
goal of the LOVAR team is to assist LVHHN and the medical 
staff with building a program of vascular preventive medicine 
and case management services for you and your patients. 
Thank you for supporting the LOVAR Study for the past three 
years. 
If you have any questions or concerns regarding the LOVAR 
Study, please contact John E. Castaldo, MD, LOVAR Principal 
Investigator, or Jane Nester, MPH, MEd, LOVAR Co-Principal 
Investigator, at (610) 402-4088. 
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Pain Management Flow Sheet 
As part of LVHHN's commitment to Pain Management and 
compliance with JCAHO Standards, a new Pain Management 
Flow Sheet has been instituted on all nursing units. The Pain 
Management Flow Sheet will be utilized for ALL patients who 
are receiving PCA or EPIDURAL analgesia, as well as patients 
who receive ANY pain medication. The flow sheet will allow 
you to better see your patients pain progress and response to 
current pain management therapy. 
As part of JCAHO regulations, the patient has a right to 
ongoing assessment of pain, interventions to help meet 
their pain goal and appropriate treatment of pain. 
A copy of the Pain Management Flow Sheet is attached on 
Page 14 for your information. 
If you have any questions regarding this issue, please contact 
Maryjane Cerrone, RN, Clinical Research Specialist, 
Neurosciences and Pain Research, at (610) 402-9003. 
Congratulations/ 
Mark A. Gittleman, MD, Division of General Surgery, 
completed Auditor Training for the American College of 
Surgeons Oncology Group (ACOSOG) and is now a certified 
Auditor for clinical trials for the ACOSOG. 
Peter A. Keblish, Jr., MD, Division of Orthopedic Surgery, 
was awarded the 2001 Sir John Charnley Award. This award 
was presented by the Arthritis Foundation at the Grand Soiree 
--An Evening of Honors held October 20 at the Blue Mountain 
Ski Area Special Events Center in Palmerton, Pa. 
The Sir John Charnley Award is given for excellence and 
achievement in the field of orthopedics. Sir John Charnley was 
an English orthopedic surgeon who invented the modem total 
hip replacement in 1962. He was a master surgeon, innovator 
and bioengineer whose techniques have been studied by 
surgeons around the world. Sir John Charnley's work has 
contributed immensely to the relief of human suffering. 
For Your Calendar 
GLVIPA General Membership meetings have been 
scheduled on the following dates: 
•:• Tuesday, March 26, 2002 
•:• Monday, June 24, 2002 
•:• Tuesday, September 24, 2002 
•:• Monday, December 16, 2002 
All meetings will begin at 6 p.m., in the Auditorium of 
Lehigh Valley Hospital, Cedar Crest & 1-78. 
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Papers, Publications and Presentations 
George A. Arangio, MD, Chief, Section of Foot and Ankle 
Surgery, co-authored an article-- "Medial displacement 
calcaneal osteotomy reduces the excess forces in the medial 
longitudinal arch of the flat foot" - which was published in 
Clinical Biomechanics 16 (2001) 535-539. 
lndru T. Khubchandani, MD, Division of Colon and Rectal 
Surgery, lectured at the Continuing Medical Education aspect 
of the Association of Colon and Rectal Surgeons of India held 
in Bombay on December 29-31, 2001. The symposium was 
telecast at the Annual Meeting of the Association of Surgeons 
of India in Patna, India. 
Later in January, 2002, Dr. Khubchandani performed a surgical 
procedure on one of the sheiks of the ruling family in Abu 
Dhabi, United Arab Emirates. 
Marisa A. Mastropietro, MD, Section of Pelvic Reconstructive 
Surgery, recently had two peer reviewed articles published. 
The first article- "Effect of Tension-Free Vaginal Tape 
Procedure on Urodynamic Continence Indices" - was 
published in Obstetrics & Gynecology, Volume 98, Number 
4, October, 2001. The second -"Detrusor Biopsy as a 
Potential Clinical Tool"-- was published in the International 
Urogynecology Journal and Pelvic Floor Dysfunction, 
Volume 12, Number6, 2001. 
Alexander D. Rae-Grant, MD, Division of Neurology, authored 
an article- "Transient Symptoms in MS"- which was 
published in the Winter, 2001 edition of Multiple Sclerosis 
Quarterly Report. 
Craig J. Sobolewski, MD, Division of Primary Obstetrics and 
Gynecology, and Residency Program Director, Department of 
Obstetrics and Gynecology, attended the American 
Association of Gynecologic Laparoscopists Global Congress of 
Gynecologic Endoscopy held in San Francisco, Calif., in 
November. "Laparoscopic Burch: Pearls Learned Over a 
Seven Year Experience," a video which Dr. Sobolewski co-
produced, was presented at the meeting. 
Howard S. Selden, DDS, Division of Endodontics, authored a 
paper- "Apexification: An Interesting Case" - which was 
published in the January 2002 issue of the Journal of 
Endodontics. 
Upcoming Seminars, Conferences and 
Meetings 
Emergency Medicine Grand Rounds 
Emergency Medicine Grand Rounds are held on Thursdays, 
beginning at 8 a.m., at alternate locations. Topics for February 
will include: 
February 7 • Banko Building, Rooms 1 & 2 
•!• Pediatric Case Review- St. Luke's Emergency Medicine 
Residency 
•!• "The Quick Diagnostic Psychiatric Interview in the ED" 
•!• "Management of the Difficult and Violent Patient" 
•!• Ten Rashes You Must Know 
February 14 ·4th Floor Conference Room· LVH·M 
•!• M & M 
•!• Resident Case Presentations 
•!• Tintinalli (Pages 539-580) 
February 21 • 4th Floor Conference Room • LVH·M 
•!• Resident Case Presentations 
•!• Alcohol Emergencies 
February 28 • 4th Floor Conference Room • LVH·M 
•!• Acute Coronary Syndrome Part II 
•!• Abdominal Pain in the Elderly 
•!• Satisfaction Guaranteed 
•:• Tintinalli (Pages 580-669) 
For more information, please contact Dawn Yenser in the 
Department of Emergency Medicine at (484) 884-2888. 
Medical Grand Rounds 
Medical Grand Rounds are held every Tuesday beginning at 
noon in the Auditorium of Lehigh Valley Hospital, Cedar Crest 
& 1-78, and via videoconference in the First Floor Conference 
Room at LVH-Muhlenberg. Topics to be discussed in 
February will include: 
•!• February 5 - "Management of the Medically Complex 
Geriatric Patient at Home" 
•!• February 12- "Hematology for the Internist" 
•!• February 19- "Life Ending Acts in the Dying Patient" 
•!• February 26 - "DVD Prophylaxis in the Hospitalized 
Patient - A Panel Discussion" 
For more information, please contact Diane Biernacki in the 
Department of Medicine at (610) 402-5200. 
(Continued on Page 11) 
, (Continued from Page 10) 
Department of Pediatrics 
Pediatric conferences are held every Tuesday beginning at 8 
a.m., in the Auditorium of Lehigh Valley Hospital, Cedar Crest 
& 1-78. Topics to be discussed in February include: 
•!• February 5 - "Medical Education: Techniques to Improve 
Teaching" 
•!• February 12- "Smiles for Tomorrow" 
•!• February 19- "Imaging the Pediatric Abdomen"- Part 2 
•!• February 26 - Case Presentation 
For more information, please contact Kelli Ripperger in the 
Department of Pediatrics at (610) 402-2540. 
General Medical Staff Meeting 
A General Medical Staff meeting will be held on Monday, 
March 11, beginning at 6 p.m., in the Auditorium of Lehigh 
Valley Hospital, Cedar Crest & 1-78, and via teleconference in 
the First Floor Conference Room at Lehigh Valley Hospital-
Muhlenberg. During the meeting, "Malpractice Suit 
Prevention" will be presented by Lawrence P. Levitt, MD, 
Division of Neurology, and Janine Fiesta, Esq., Vice President, 
Legal Services. All members of the Medical Staff are 
encouraged to attend. 
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Who's New 
The Who's New section of Medical Staff Progress Notes 
contains an update of new appointments, address changes, 
resignations, etc. Please remember to update your directory 
and rolodexes with this information. 
Medical Staff 
Appointments 
Eugene B. Nor, MD 
Christine & Bren Family Practice 
1365 Blue Mountain Drive 
Danielsville, PA 18038-9738 
(610) 767-4315 
Fax: (610) 767-9420 
Department of Family Practice 
Site of Privileges - None 
Provisional Affiliate 
Susan K. Pedott, DMD 
(Solo Practice) 
3894 Courtney Street, Suite 1 05 
Bethlehem, PA 18017-8920 
(610) 317-2400 
Fax: (610) 317-8600 
Department of Dentistry 
Division of Endodontics 
Site of Privileges - LVH & LVH-M 
Provisional Active 
Gary W. Szydlowski, MD 
The Heart Care Group, PC 
Jaindl Pavilion, Suite 500 
1202 S. Cedar Crest Blvd. 
P.O. Box 3880 
Allentown, PA 18106-0880 
(610) 770-2200 
Fax: (610) 776-6645 
Department of Surgery 
Division of Cardia-Thoracic Surgery 
Section of Cardiac Surgery 
Site of Privileges - LVH & LVH-M 
Provisional Active 
Address Changes 
Lehigh Valley Foot and Ankle Surgeons 
•!• Jay H. Kaufman, DPM 
•!• Dean L. Sorrento, DPM 
1575 Pond Road, Suite 202 
Allentown, PA 18104-2254 
(Effective February 15, 2002) 
(Continued on Page 12) 
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Laurence P. Karper, MD 
LVPG-Psychiatry 
Lehigh Valley Hospital-Muhlenberg 
2545 Schoenersville Road 
5th Floor 
Bethlehem, PA 18017-7384 
(484} 884-6503 
Fax: (484) 884-6504 
Michael W. Kaufmann, MD 
LVPG-Psychiatry 
Lehigh Valley Hospital-Muhlenberg 
2545 Schoenersville Road 
5th Floor 
Bethlehem, PA 18017-7384 
( 484} 884-6503 
Fax: (484) 884-6504 
Susan D. Wiley, MD 
LVPG-Psychiatry 
1255 S. Cedar Crest Blvd., Suite 3800 
Allentown, PA 18103-6256 
(610) 821-2036 
Fax: (610} 821-2038 
Practice Change. 
Brendan J. O'Brien, DO 
(No longer associated with Coordinated Health Systems} 
Orthopaedic Associates of Allentown 
1243 S. Cedar Crest Blvd. 
Second Floor 
Allentown, PA 18103-6268 
(610) 433-6045 
Fax: (610) 433-3605 
Status Changes 
Frank G. Baloh, MD 
Department of Surgery 
Division of Ophthalmology 
From: Active 
To: Affiliate 
Site of Privileges - None 
Thomas 0. Burkholder, MD 
Department of Surgery 
Division of Ophthalmology 
From: Associate 
To: Affiliate 
Site of Privileges - None 
Joseph J. Grassi, MD 
Department of Medicine 
Division of Physical Medicine-Rehabilitation 
From: Provisional Active 
To: Associate 
Site of Privileges - LVH-M 
Joseph Kavchok, Jr., MD 
Department of Surgery 
Division of Ophthalmology 
From: Active 
To: Affiliate 
Site of Privileges - None 
Dennis W. Kean, MD 
Department of Pediatrics 
Division of General Pediatrics 
From: Active/LOA 
To: Honorary 
Robert Kiesel, MD 
Department of Surgery 
Division of Ophthalmology 
From: Associate 
To: Affiliate 
S~e of Privileges - None 
Howard J. Kushnick, MD 
Department of Surgery 
Division of Ophthalmology 
From: Active 
To: Affiliate 
Site of Privileges - None 
Alan B. Leahey, MD 
Department of Surgery 
Division of Ophthalmology 
From: Active 
To: Affiliate 
Site of Privileges - None 
Alan D. Listhaus, MD 
Department of Surgery 
Division of Ophthalmology 
From: Active 
To: Affiliate 
Site of Privileges - None 
Mamie P. O'Brien, DO 
Department of Surgery 
Division of Ophthalmology 
From: Active 
To: Affiliate 
Site of Privileges - None 
(Continued on Page 13) 
Page 12 
. (Continued from Page 12) 
One-Year Leave of Absence 
Steven L. Zelenkofske, DO 
Department of Medicine 




John R. Anderson, MD 
Department of Surgery 
Division of Urology 
William F. Gadbois, MD 
Department of Surgery 
Division of Urology 
Karen M. Matz, MD 
F 
Department of Obstetrics and Gynecology 
Division of Primary Obstetrics and Gynecology 
Peter J. Meyer, MD 
Department of Psychiatry 
Section of Child-Adolescent Psychiatry 
Death 
Raul M. Abad, MD 
Department of Surgery 
Division of Neurological Surgery 
Allied Health Staff 
Appointments 
Guy T. Hornig, CRNA 
Physician Extender 
Professional - CRNA 
(Lehigh Valley Anesthesia Services, Inc. - Thomas M. 
McLoughlin, Jr., MD) 
Site of Privileges - LVH & LVH-M 
David J. lsgan, PA·C 
Physician Extender 
Physician Assistant - PA-C 
(Gastroenterology Associates- Lawrence W. Barclawil, MD) 
Site of Privileges - L VH & LVH-M 
Craig I. Matsumoto, CNIM 
Physician Extender 
Technical 
Intraoperative Neurophysiological Monitoring Specialist 
(Surgical Monitoring Associates) 
(Supervising Physician - Marl< C. Lester, MD) 
Site of Privileges - LVH & LVH-M 
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Heather L. Posavek, GRNA 
Physician Extender 
Professional - GRNA 
(Lehigh Valley Anesthesia Services, Inc. - Thomas M. 
McLoughlin, Jr., MD) 
Site of Privileges - LVH & LVH-M 
William R. Sevold 
Physician Extender 
Technical- Pacemaker/ICD Technician 
(Guidant Corp) 
(Supervising Physician - Norman H. Marcus, MD) 
Site of Privileges - LVH & LVH-M 
Mark E. Unger, CRNA 
Physician Extender 
Professional - CRNA 
(Anesticare Anesthesia Services Inc) 
(Supervising Physician -Thomas M. McLoughlin, Jr., MD) 
Site of Privileges - Lehigh Magnetic Imaging Center only 
Resignations 
Donald G. Connell, CRNA 
Physician Extender 
Professional - CRNA 
(Allentown Anesthesia Associates Inc) 
John E. Kresge, CRNA 
Physician Extender 
Professional - CRNA 
(Allentown Anesthesia Associates Inc) 
Michael C. Loomis, CRNA 
Physician Extender 
Professional - CRNA 
(Allentown Anesthesia Associates Inc) 
Terrance McGinley, CRNA 
Physician Extender 
Professional - CRNA 
(Allentown Anesthesia Associates Inc) 
Ann J. Peiffer, PA-C 
Physician Extender 
Physician Assistant- PA-C 
(Opcor, P.C.) 
William J. Waldron, CRNA 
Physician Extender 
Professional - CRNA 
(Allentown Anesthesia Associates Inc) 
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THERAPEUTICS AT A GLANCE 
The following actions were taken at the December 2001 Therapeutics Committee Meeting- Joseph Ottinger, R.Ph., MS, MBA, Janine Barnaby, 
R.Ph., Jenny Boucher, Pharm.D., Viraj Patel, Pharm.D, Kimberly Pettis, R.D. 
Formulary Additions 
Nesiritide/Natrecor ™ 
N esiritide is indicated for the intravenous treatment of patients with acutely decompensated congestive heart failure 
who have dyspnea at rest or with minimal activity. 
Human b-type (brain) natriuretic peptide is an endogenous 32-amino acid peptide hormone found in brain and 
cardiac tissue that exerts cardiovascular and renal activity. Although originally identified in porcine brain tissue, 
it is now recognized to be excreted primarily by the cardiac ventricle. Nesiritide is synthetic human b-type 
natriuretic peptide and is identical in amino acid sequence to the naturally occurring hormone. It is produced by 
E. coli using recombinant DNA technology. 
B-type natriuretic peptide is a vasodilator, reducing both preload and afterload, with additional diuretic and 
natriuretic activity. B-type natriuretic peptide is structurally and functionally similar to atrial natriuretic peptide 
(ANP). Levels ofboth endogenous peptides are increased in fluid overload states including congestive heart failure 
and chronic renal failure. Normally, b-type natriuretic peptide levels are lower than those of atrial natriuretic 
peptide; however, levels rise with cardiac injury in proportion to the severity of cardiac dysfunction and may exceed 
atrial natriuretic peptide levels. In severe heart failure, levels ofb-type natriuretic peptide are greatly elevated (20 
to 1 00-fold). It is believed that the two hormones play a complementary role in modulating cardiac function and 
fluid status. 
Nesiritide was associated with reduction in pulmonary wedge pressure, mean right atrial pressure, and systemic 
vascular resistance, and increases in cardiac index and stroke volume index, with no effect on heart rate. 
Following administration of the recommended nesiritide dosing regimen (2 meg/kg IV bolus followed by an 
intravenous infusion dose ofO.Ol meg/kg/min), 60% of the 3-hour effect on pulmonary capillary wedge pressure 
reduction is achieved within 15 minutes after the bolus. Within 1 hour, 95% of the 3-hour effect is achieved. 
Approximately 70% of the 3-hour effect on systolic blood pressure reduction is achieved within 15 minutes. After 
discontinuation or reduction of dose in patients with symptomatic hypotension, half of the recovery of the systolic 
blood pressure toward baseline is observed in about 60 minutes. At higher doses, the duration of hypotension has 
been prolonged to several hours· Pulmonary capillary wedge pressure returns to within 1 0% of baseline within 2 
hours after discontinuation of nesiritide. 
The effects of nesiritide persist longer than would be expected from the short half-life, possibly due to receptor-
mediated hemodynamic effects. 
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Natriuretic peptides are cleared from the circulation by three mechanisms: binding to natriuretic peptide clearance 
receptors on endothelial cells resulting in cellular internalization and lysosomal proteolysis; proteolytic cleavage 
by endopeptidases, such as neutral endopeptidases; and renal filtration. 
Although nesiritide is partially eliminated through renal filtration, dosage adjustment is not required in patients with 
renal insufficiency. 
Nesiritide should not be used as primary therapy for patients with cardiogenic shock or in patients with a systolic 
blood pressure less than 90 mmHg. Nesiritide use should also be avoided in patients suspected of having or known 
to have low cardiac filling pressures. 
It is not recommended for patients for whom vasodilating agents are not appropriate, such as patients with valvular 
stenosis, restrictive or obstructive cardiomyopathy, constrictive pericarditis, pericardia! tamponade, or other 
conditions in which cardiac output is dependent upon venous return. 
At higher doses, hypotensive episodes occurred more frequently and were generally of greater intensity and duration 
and more frequently required medical intervention. Administration of nesiritide is recommended only in settings 
where blood pressure can be monitored closely. The nesiritide dose should be reduced or nesiritide therapy 
discontinued if hypotension occurs. Nesiritide should be administered cautiously in patients with a systolic blood 
pressure less than 100 mmHg at baseline. The potential for hypotension may also be increased when nesiritide is 
administered with other medications that may cause hypotension, such as an ACE inhibitor. 
Nesiritide may affect renal function. In patients with severe heart failure whose renal function may depend on the 
activity of the renin-angiotensin-aldosterone system, treatment with nesiritide may be associated with azotemia. 
At doses higher than 0.01 meg/kg/min, an increased rate of elevated serum creatinine over baseline compared with 
other therapies was observed, although the rate of acute renal failure and need for dialysis was not increased. 
The most common adverse effects have included hypotension and associated symptoms including headache, nausea, 
substernal pain, diaphoresis, lightheadedness, and sinus bradycardia. Other adverse effects reported in clinical trials 
have included palpitations, vomiting, superficial phlebitis, epigastric discomfort, and junctional rhythm. 
Hypotension and nausea appear to occur more frequently at higher doses. Table 2 summarizes the adverse effects 
occurring with at least 3% frequency during the first 24 hours of nesiritide infusion in several clinical trials. 
In clinical trials, nesiritide has been administered concomitantly with diuretics, oral ACE inhibitors, digoxin, oral 
vasodilators, dobutamine, anticoagulants, oral nitrates, statins, class III antiarrhythmic agents, beta-blockers, 
calcium channel blockers, angiotensin II receptor antagonists, and dopamine. The coadministration of nesiritide 
with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated 
and these agents were not coadministered with nesiritide in clinical trials. 
Nesiritide is administered intravenously. Blood pressure should be closely monitored during nesiritide 
administration. If hypotension occurs during nesiritide administration, the dose should be reduced or discontinued 
and other measures to support blood pressure should be started (IV fluids, changes in body position). In the VMAC 
trial, nesiritide therapy was discontinued when symptomatic hypotension occurred and could be subsequently 
restarted at a dose that was reduced by 30% (with no bolus administration) once the patient was stabilized. 
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Hypotension may be prolonged up to hours; therefore, a period of observation may be necessary before restarting 
nesiritide. 
The recommended dose ofnesiritide is an IV bolus of2 meg/kg followed by a continuous infusion at a dose of0.01 
meg/kg/min. Therapy should not be initiated at a higher dose. The infusion solution should be prepared by adding 
1.5 mg to 250 ml of solution, resulting in a concentration of 6 mcg/mL of nesiritide. The IV tubing should be 
primed with an infusion of25 mL prior to connecting the patient's vascular access port and prior to administering 
the bolus or starting the infusion. To administer the bolus dose, the bolus volume recommended in Table 1 should 
be withdrawn from the infusion bag and administered over approximately 60 seconds through an IV port in the 
tubing. Immediately after administration of the bolus dose, an infusion should be initiated at a flow rate of 0.1 
mL/kg/hr that will deliver a nesiritide infusion dose ofO.O 1 meg/kg/min. Table 1 or the following fonnulas should 
be used to calculate the appropriate weight-based bolus volume and infusion flow rate: 
Bolus volume (mL) = 0.33 x patient weight (kg) 
Infusion flow rate (mL/hr) = 0.1 x patient weight (kg) 
Table 1: Weight-Based Bolus Volume and Infusion Flow Rate: 
Patient Weight Volume of Bolus Rate of Infusion 
(kg) (mL) (mi.Jh) 
60 20 6 
70 23.3 7 
80 26.7 8 
90 30 9 
100 ' 33.3 10 
110 36.7 11 
In the VMAC trial, 23 patients who had central hemodynamic monitoring received increased doses of nesiritide. 
The infusion dose was increased by 0.005 meg/kg/min no more frequently than every 3 hours up to a maximum dose 
of 0.03 meg/kg/min. Nesiritide should not be titrated at frequent intervals. There is limited experience with 
administration of nesiritide for longer than 48 hours. 
Nesiritide is physically and/or chemically incompatible with injectable fonnulations ofheparin, insulin, ethacrynate 
sodium, bumetamide, enalaprilat, hydralazine, and furosemide. Nesiritide should not be coadministered with these 
agents through the same IV catheter. The preservative sodium metabisulfite is also incompatible with nesiritide 
and injectable drugs containing sodium metabisulfite should not be administered in the same infusion line as 
nesiritide. The catheter must be flushed between administration of nesiritide and incompatible agents. Nesiritide 
binds heparin and could bind the heparin lining of a heparin-coated catheter, thereby reducing nesiritide delivery 
to a patient. Nesiritide must not be administered through a central heparin-coated catheter. 
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Table 2: Adverse Events Reported in the Product Labeling ofNesiritide: 
Adverse Event 1 VMAC Trial I Other Trials 
Nitrogly-cerin Nesiritide Control* Nesiritide Nesiritide 
(n=216) (n=273) (n=256) 0.015 meg/kg/min 0.03 meg/kg/min 
(n=253) (n=246) 
Cardiovascular 
Hypotension 12% 11% 8% 22% 35% 
Symptomatic hypotension 5% 4% 3% 11% 17% 
Asymptomatic hypotension 8% 8% 5% 12% 20% 
Ventricular tachycardia (VT) 5% 3% 10% 10% 4% 
Non-sustained VT 5% 3% 9% 9% 4% 
Ventricular extrasystoles 1% 3% 6% 4% 4% 
Angina pectoris 2% 2% 2% 6% 2% 
Bradycardia <1% 1% <1% 3% 5% 
Body as a Whole 
Headache 20% 8% 9% 9% 7% 
Abdominal pain 5% 1% 4% 2% 3% 
Back pain 3% 4% 2% 2% 1% 
Central Nervous System 
Insomnia 4% 2% 3% 6% 6% 
Dizziness 2% 3% 3% 6% 5% 
Anxiety 3% 3% 1% 3% 2% 
Digestive 
Nausea 6% 4% 6% 9% 13% 
Vomiting 2% 1% 1% 2% 4% . . *includes dobutamme, mtlrinone, mtroglycerm, placebo, dopamme, mtroprusstde, or amrmone . 
CONCLUSION: Nesiritide may offer an alternative to dobutamine, nitroglycerin, nitroprusside, milrinone and 
other agents used in the therapy of hospitalized patients with acute congestive heart failure. It may be less likely 
to cause ventricular arrhythmias than dobutamine, but was associated with a high incidence of symptomatic 
hypotension in earlier trials, which featured higher dosing regimens. The reduced dosage used in the VMAC study 
and approved by the FDA resulted in a comparable incidence of hypotension V s. nitroglycerin. Nesiritide therapy 
does help to lower the pulmonary capillary wedge pressure and improve other hemodynamic parameters in 
hospitalized patients with decompensated heart failure, but its comparative advantages have not been clearly 
illustrated in any trial to date. Additional comparative data are necessary to determine the role of nesiritide in the 
therapy of acute congestive heart failure. A provisional formulary availability status was approved to allow for 
cardiology to gain some experience with this agent in the treatment of acute decompensated congestive heart failure. 
The Pharmacy will monitor patients receiving this agent and report back to the Therapeutics Committee its findings. 
Twenty-four hours of therapy with nesiritide for an 80 kg patient (one vial) will cost $370, while comparable 
therapy with milrinone would cost $360. Nitroglycerin infusion bottles currently cost the institution@ $1.10 per 
1 00mg/250ml bottle. Three bottles would be required to treat an 80 kg patient at 200 meg/minutes for 24 hours. 
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Dobutamine infusion dosed at 1 0 meg/kg min for this same patient would require 5 vials of 250mg for a 24 hour 
treatment-costing $16.25. Nitroprusside infusion in this same scenario would cost $26.40. 
Etomidate/Amidate 
Etomidate is a hypnotic drug without analgesic activity. Intravenous injection of etomidate produces hypnosis 
characterized by a rapid onset of action, usually within 1 minute. Duration of hypnosis is dose dependent but 
relatively brief, usually 3-5 minutes when an average dose of 0.3 mglkg is employed. Immediate recovery from 
anesthesia (as assessed by awakening time, time needed to follow simple commands and time to perform simple 
tests after anesthesia as well as they were performed before anesthesia), based upon data derived from short 
operative procedures where intravenous etomidate was used for both induction and maintenance of anesthesia, is 
about as rapid as, or slightly faster than, immediate recovery after similar use of thiopental. 
The most characteristic effect of intravenous etomidate on the respiratory system is a slight elevation in arterial 
carbon dioxide tension (PaC02). 
Reduced cortisol plasma levels have been reported with induction doses of0.3 mglkg etomidate. These persist for 
approximately 6-8 hours and appear to be unresponsive to ACTH administration. 
The intravenous administration of up to 0.6 mglkg of etomidate to patients with severe cardiovascular disease has 
little or no effect on myocardial metabolism, cardiac output, peripheral circulation or pulmonary circulation. The 
hemodynamic effects of etomidate have in most cases been qualitatively similar to those of thiopental sodium, 
except that the heart rate tended to increase by a moderate amount following administration of thiopental under 
conditions where there was little or no change in heart rate following administration of etomidate. There are 
insufficient data concerning use of etomidate in patients with recent severe trauma or hypovolemia to predict 
cardiovascular response under such circumstances. 
Clinical experience and special studies to date suggest that standard doses of intravenous etomidate ordinarily 
neither elevate plasma histamine nor cause signs of histamine release. 
Etomidate is rapidly metabolized in the liver. 
Etomidate is indicated by intravenous injection for the induction of general anesthesia. When considering use of 
etomidate, the usefulness of its hemodynamic properties should be weighed against the high frequency of transient 
skeletal muscle movements. 
Intravenous etomidate is also indicated for the supplementation of subpotent anesthetic agents, such as nitrous oxide 
in oxygen, during maintenance of anesthesia for short operative procedures such as dilation and curettage or cervical 
conization. 
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BECAUSE OF THE HAZARDS OF PROLONGED SUPPRESSION OF ENDOGENOUS CORTISOL AND 
ALDOSTERONE PRODUCTION, THIS FORMULATION IS NOT INTENDED FOR ADMINISTRATION BY 
PROLONGED 
INFUSION. 
Plasma Cortisol Levels Induction doses of etomidate have been associated with reduction in plasma cortisol and 
aldosterone concentrations. These have not been associated with changes in vital signs or evidence of increased 
mortality; however, where concern exists for patients undergoing severe stress, exogenous replacement should be 
considered. 
The most frequent adverse reactions associated with use of intravenous etomidate are transient venous pain on 
injection and transient skeletal muscle movements, including myoclonus: 
Transient venous pain was observed immediately following intravenous injection of etomidate in about 20% of the 
patients, with considerable difference in the reported incidence (1.2-42%). This pain is usually described as mild 
to moderate in severity but it is occasionally judged disturbing. The observation of venous pain is not associated 
with a more than usual incidence of thrombosis or thrombophlebitis at the injection site. Pain also appears to be less 
frequently noted when larger, more proximal ann veins are employed and it appears to be more frequently noted 
when smaller, more distal, hand or wrist veins are employed. 
Transient skeletal muscle movements were noted following use of intravenous etomidate in about 32% of the 
patients, with considerable difference in the reported incidence (22. 7-63% ). Most of these observations were judged 
mild to moderate in severity but some were judged disturbing. The incidence of disturbing movements was less 
when 0.1 mg of fentanyl was given immediately before induction. These movements have been classified as 
myoclonic in the majority of cases (74%), but averting movements (7%), tonic movements (10%), and eye 
movements (9%) have also been reported. No exact classification is available, but these movements may also be 
placed into three groups by location: 
Most movements are bilateral. The anns, legs, shoulders, neck, chest wall, trunk and all four extremities have been 
described in some cases, with one or more of these muscle groups predominating in each individual case. 
Results of electroencephalographic studies suggest that these muscle movements are a manifestation of 
disinhibition of cortical activity; cortical electroencephalograms, taken during periods when these muscle 
movements were observed, have failed to reveal seizure activity. 
Other movements are described as either unilateral or having a predominance of activity of one side over the other. 
These movements sometimes resemble a localized response to some stimuli, such as venous pain on injection, in 
the lightly anesthetized patient (averting movements). Any muscle group or groups may be involved, but a 
predominance of movement of the ann in which the intravenous infusion is started is frequently noted. 
Still other movements probably represent a mixture of the first two types. Skeletal muscle movements appear to be 
more frequent in patients who also manifest venous pain on injection. 
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Other Adverse Observations include the following: 
Respiratory System: Hyperventilation, hypoventilation, apnea of short duration (5-90 seconds with spontaneous 
recovery), laryngospasm, hiccup and snoring suggestive of partial upper airway obstruction have been observed in 
some patients. These conditions were managed by conventional countermeasures. 
Circulatory System: Hypertension, hypotension, tachycardia, bradycardia and other arrhytlunias have occasionally 
been observed during induction and maintenance of anesthesia. One case of severe hypotension and tachycardia, 
judged to be anaphylactoid in character, has been reported. 
Gastrointestinal System: Postoperative nausea and/or vomiting following induction of anesthesia with etomidate 
is probably no more frequent than the general incidence. When etomidate was used for both induction and 
maintenance of anesthesia in short procedures such as dilation and curettage, or when insufficient analgesia was 
provided, the incidence of postoperative nausea and/or vomiting was higher than that noted in control patients who 
received thiopental. 
Etomidate injection is intended for administration only by the intravenous method. The dose for induction of 
anesthesia in adult patients and in children above the age of 10 years will vary between 0.2 and 0.6 mg/kg ofbody 
weight, and it must be individualized in each case. The usual dose for induction in these patients 0.3 mg/kg, injected 
over a period of 30-60 seconds. There are inadequate data to make dosage recommendations for induction of 
anesthesia in patients below the age of 10 years; therefore, such use is not recommended. 
Smaller increments of intravenous etomidate may be administered to adult patients during short operative 
procedures to supplement subpotent anesthetic agents, such as nitrous oxide. The dosage employed under these 
circumstances, although usually smaller than the original induction dose, must be individualized. There are 
insufficient data to support this use of etomidate for longer adult procedures or for any procedures in children; 
therefore, such use is not recommended. The use of intravenous fentanyl and other neuroactive drugs employed 
during the conduct of anesthesia may alter the etomidate dosage requirements. 
Conclusion: Etomidate has been utilized for almost 20 years. It is considered a safe and effective induction agent 
The current cost for etomidate 40mg/20ml is $13.90. An induction dose of 0.2mg/kg of etomidate will cost about 
$7.00. An equivalent dose of thiopental would cost $3.50. Its selected use in anesthesia and the ER areas is 
anticipated. 
Valganciclovir Hydrochloride/ Valcyte ™ 
V alganciclovir has been recommended for approval for use in the induction and maintenance treatment of 
cytomegalovirus retinitis in patients with AIDS. Table 1 compares the other agents approved for this indication. 
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Table 1: Antiviral Agents Used in the Treatment ofCMV Retinitis: 
Generic Name Cidofovir Fomivirsen Foscarnet Ganciclovir Ganciclovir Ganciclovir Valgan-
Cidofovir Insert IV PO ciclovir 
Cidofovir 
Brand Name Vis tide Vitravene Foscavir Vitrasert Cytovene-IV Cytovene Va/cyte 
Manufacturer Gilead Ciba Vision AstraZeneca Bausch & Roche Roche Roche 
Lomb 
Indications 
CMV retinitis in X X 
immunocompromised 
patients, including 
patients with AIDS 
CMV retinitis in X X X xa 
patients with AIDS 
CMV retinitis in 
patients with AIDS 
who are intolerant of or 
have a contraindication 
to other treatments for 
CMV retinitis or who 
were insufficiently 
responsive to previous 
treatments 
Induction X xxxx X X xa 
Maintenance X X X X X X xa 
Combination therapy in X 
CMV retinitis 
Prevention of CMV X X 
disease in organ 
transplant recipients 
Prevention of CMV X 
disease in patients with 






a~ant1c1pated upon approval 
Valganciclovir is rapidly and completely hydrolyzed to ganciclovir following oral administration. The absolute 
bioavailability of ganciclovir from valganciclovir is approximately 60%. In contrast, the bioavailability of oral 
ganciclovir is about 6%. Unlike ganciclovir, valganciclovir is a substrate of the intestinal peptide transporter PEPTI, 
resulting in its increased bioavailability. Hepatic and intestinal esterases rapidly convert valganciclovir to 
ganciclovir. 
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Phase III studies are ongoing with valganciclovir for the prevention of CMV retinitis in solid organ transplant 
recipients. The manufacturer is currently conducting a double-blind, multicenter study comparing valganciclovir 
900 mg once daily and oral ganciclovir 1000 mg three times daily for the prevention of CMV disease in high-risk 
heart, liver, and kidney allograft recipients. 
The contraindications, warnings, and precautions for valganciclovir are similar to those of ganciclovir .. 
The most frequently observed adverse events during valganciclovir induction therapy included diarrhea, nausea, 
vomiting, fever, fatigue, headache, oral candidiasis, neutropenia, anemia, and thrombocytopenia 
Diarrhea occurred more frequently with valganciclovir than IV ganciclovir (16% vs 10% ); however, nausea occurred 
more frequently with IV ganciclovir (14% vs 8%). During valganciclovir maintenance therapy, 29% of patients 
treated with valganciclovir induction therapy developed hemoglobin levels below 8 g/d.L compared to 16% of 
patients who had received IV ganciclovir. 
As valganciclovir is rapidly converted to ganciclovir, the drug interactions associated with ganciclovir will also 
apply to valganciclovir. Seizures have been reported in patients who received ganciclovir and imipenem-cilastatin; 
therefore, concomitant use is not recommended unless the potential benefits outweigh the risks. 
Drugs that inhibit replication of rapidly dividing cell populations such as bone marrow, spermatogonia, and 
germinal layers of skin and gastrointestinal mucosal may have additive toxicity when administered with ganciclovir. 
Such agents would include dapsone, pentamidine, flucytosine, vincristine, vinblastine, doxorubicin, amphotericin 
B, co-trimoxazole, or other nucleoside analogs. 
Recommended monitoring should be similar to that for ganciclovir and includes frequent complete blood counts 
and platelet counts, especially in patients with a history of leukopenia during ganciclovir therapy or in whom 
neutrophils counts are less than 1000 cells/mL upon initiation of therapy. Serum creatinine or creatinine clearance 
should also be closely monitored to allow for dosage adjustments in patients with renal impairment. 
The dose evaluated in the primary clinical trial in patients with AIDS and CMV retinitis used an oral valganciclovir 
dose of 900 mg twice daily for 21 days during induction therapy followed by 900 mg once daily for maintenance 
therapy. 
CONCLUSION: Valganciclovir appears to offer a promising alternative to oral and intravenous ganciclovir, with 
the advantage of once- or twice-daily oral administration. It appears to achieve ganciclovir levels comparable to 
those achieved with the intravenous administration of ganciclovir, and appeared as effective as intravenous 
ganciclovir in the induction therapy of CMV retinitis in patients with AIDS. Although the efficacy of the 
valganciclovir in maintenance therapy has not been established in clinical trials, there is no reason to believe it 
should not be as effective as oral or intravenous ganciclovir in maintenance therapy based on the levels of 
ganciclovir achieved in pharmacokinetic studies. The adverse effects ofvalganciclovir appear comparable to those 
of ganciclovir. Currently, 1 gram of oral ganciclovir administered thrice daily would cost $75.00/day, while 
900mg/daily ofvalganciclovir costs $46.75. 
The improved bioavailability of this agent makes it especially attractive in the regimens of renal transplant 
patients. 
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Angiotensin Receptor (ARBs) Formulary Streamlined 
No study has shown any of these agents to be preferable over the angiotensin converting enzyme inhibitors (ACEI) 
in controlling blood pressure, improving the clinical status of patients with heart failure (sans ELITE 1) or in use 
in mitigating the effects of diabetic nephropathy. Although, in patients that can not tolerate ACEI therapy, 
angiotensin receptor blockers may provide an alternative in these situations. Certainly, no published comparative 
study has suggested that any of the individual molecules has any superiority vs. other members of this drug class 
in these two latter areas. 
Based on the limited comparative studies in hypertension, irbesartan was at least as effective as either losartan or 
valsartan. Candesartan was considered equivalent to losartan at low doses and statistically superior to losartan in 
higher doses in one study. Irbesartan and candesartan have the most bioavailability amongst all the currently 
available agents and can be dosed on a once daily basis. Both products have no demonstrated food/drug 
interactions. Candesartan does require biotransformation, but this is not a clinically relevant limitation. Neither 
agent requires dosing modifications in renal dysfunction. As candesartan will provide some marginal cost savings 
and it allows for a stratified dose adjustment across multi-product dosage ranges, it was selected as the primary 
angiotensin receptor blocking (ARB) agent for the LVH Formulary. Losartan will also remain on the Formulary 
for its unique uricosuric effects and its current high frequency of use amongst this class of drugs. 
Candesartan will be substituted for the other current ARBs based on the dosing schedule elucidated below. Patients 
on losartan therapy WILL NOT have their therapy modified. 
Approved Dose conversions (based on total daily doses) 
Candesartan lrbesartan Valsartan 
4mg 75mg 80mg 
8mg 150mg 160mg 
16mg 225mg 240mg 
32mg 300mg 320mg 
Candesartan Telmisartan Eprosartan 
8mg 40mg 600mg 
8mg 40mg 600mg 
16mg 80mg 400mg bid 
16mg 80mg 400mg bid 
Comparative Acquisition Costs for ARBs based on Total Daily Dosage 
Losartan Valsartan Candesartan Telmisartan Eprosartan lrbesartan 
2Smg=$1.02 SOmg=$1.04 4mg=$1.10 40mg=S1.11 600mg=$1.07 7Smg=$1.11 
SOmg=$1.02 160mr-$1.13 Smr-$1.10 150mg=$1.17 
7Smg=$2.04 240mg=S2.17 16mg=$1.10 SOmg=$1.18 800m_rl1.60 22Smg=S2.18 
100mg=$1.46 320mg=$2.16 32mg=S1.47 300mg=S1.33 
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Comparative Pharmacology 
Parameter Losartan Valsartan Irbesartan Candesartan Telmistartan Eorosartan 
Food 10% SO% None None 20% Delaied 
Interactions decrease decrease decrease absorotion 
Drug RifamJ!in, None None None Digoxin None 
Interactions fluconazole 
Metabolism 2C9and 3A4 Unknown Glucuronide 0- Minimal Glucuronide 




T Yz {hr} 2 (meta 6-9) 6 11-15 4 lmeta 3-1n 24 S-9 
HeJ!atic Decrease Unknown Unknown Unknown No Change No Change 
disfunction initial dose Change in Change in Change in 
~ ~ ~ 
disease disease disease 
Renal No Change Unknown No Change No Change Unknown No Chang:e 
disfunction Chang:e in Chang:e in 
(If NOT ~ ~ 
volume disease disease 
depleted) 
Active Yes No No Yes No No 
metabolite 
Additional Proton Pump Inhibitor Autosubstitutions 
The Therapeutics committee approved therapeutic substitutions for two additional agents in the proton pump 
inhibitor category. The Phannacy was authorized to change rabeprazole (Aciphex) and esomeprazole (Nexium) 
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Abbreviation/Dose 
!Intended Meaning "Misinterpretation !!correction I Expression 
'Apothecary symbols ll:~n~m I Misunderstood or misread (symbol for dram misread for "3" and minim misread as "mL"). IUse the metric system. I 
!Au llaurio uterque (each ear) IIMistaken for OU (oculo uterque-each eye). lloon't use this abbreviation. I 
IDIC I discharge 
Premature discontinuation of medications when D/C (intended to Use "discharge" and mean "discharge") has been misinterpreted as "discontinued" "discontinue." . d1scontmue when followed by a list of drugs. 
!Drug names 
II I 
Use the complete spelling for 
drug names. 
IARNA llvidarabine llcytarabineARA •c I 






II chlorpromazine I I 
IDPT IDEMEROL- ldiphtberi,_portu,.,i•-t-"' ( v"dne) I PHENERGAN-THORAZINE 
jHCl llhydrochloric acid llpotassium chloride (The "H" is misinterpreted as "K.") 
jHCT !!hydrocortisone ijhydrochlorothiazide 
!HCTZ jjhydrochlorothiazide llhydrocortisone (seen as HCT250 mg) 
IMgS04 llmagnesium sulfate llmorphine sulfate 
jMS04 llmorphine sulfate llmagnesium sulfate 
IMTX llmethotrexate llmitoxantrone I 
ITAC lltriamcinolone lltetracaine, ADRENALIN,cocaine J 
jznS04 jjzinc sulfate llmorphine sulfate J 
!stemmed names I II 
!"Nitro" drip jjnitroglycerin infusion II sodium nitroprusside infusion I 
I"Norflox" llnorfloxacin IINORFLEX I 
Ill g lirnicrogram !!Mistaken for "mg" when handwritten. I!Use ''meg." I 
,o.d. orOD llonce daily I Misinterpreted as "right eye" (OD-oculus dexter)and 
administration of oral medications in the eye. 
IUse "daily." I 
lnwortiw llthree times a week. I!Mistaken as "three times a day." llnon't use this abbreviation. I 
!per os II orally liThe "os" can be mistaken for "left eye." I Use "PO," "by mouth," or 
"orally." 
,q.d. orQD llevery day I Mistaken as q.i.d., especially if the period after the "q" or the tail Use "daily" or "every day." 
of the "q" is misunderstood as an "i." 
lqn llnightly or at bedtime I!Misinterpreted as "qh" (every hour). lluse "nightly." I 
jqhs !!nightly at bedtime IIMisread as every hour. lluse "nightly." I 
lq6PM, etc. II every evening at 6 PM IIMisread as every six hours. lluse 6 PM "nightly." I 
,q.o.d. or QOD llevery other day I Misinterpreted as "q.d." (daily) or "q.i.d. (four times daily) if the 
"o" is poorly written. 
I Use "every other day." I 
l'ubq ll'uboumneo"' I The "q" has been mistaken for "every" (e.g., one heparin dose Use "subcut." or write "subcutaneous." ordered "sub q 2 hours before surgery" misunderstood as every 2 
hours before surgery). 
jsc II subcutaneous "Mistaken for SL (sublingual). I Use "subcut." or write 
"subcutaneous." 
IU oru llunit I Read as a zero (0) or a four (4), causing a 10-fold overdose or jj;'Unit" has no acceptable greater (4U seen as "40" or 4u seen as 44"). abbreviation. Use "unit." 
lw llintemational unit I!Misread as IV (intravenous). lluse "units." I 
Icc llcubic centimeters IIMisread as "U" (units). lluse "mL." I 
lx3d l!for three days IIMistaken for "three doses." lluse "for three days." I 
IBT llbedtime IIMistaken as "BID" (twice daily). lluse "hs." I 
II II II 
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Iss I sliding scale (insulin) or 'h 'Mistaken for "55." llspell out "sliding scale." Use I ~· ================~·~(a=po=t=h=ec=my==)========~~· ~======~======~======================~ll~·=·o=n=e-=h=ru=f='o=r=u=se=="Y,=2·="====~I 
~~'>==;m=d=<==========l' greater than and less than 'Mistakenly used opposite of intended. I ~:::reater than" or "less 
1
/ (slash mark) I separates two doses or Misunderstood as the number I ("25 unit/10 units" read as "110" Do not use a slash mark to 
indicates "per" units. separate doses. 
Use"per." 
1:=======~ 
Name letters and dose llnderal 40 mg IIMisread as lnderal 140 mg. I Always use space between 
numbers run together drug name, dose and unit of 
~(e=.g~··=m=d=e=ra=l4=0=m=g=)====~~================~?======================================~?m=e=as=u=re=·============~ 
Zero after decimal point II mg I Misread as 1 0 mg if the decimal point is not seen. Do not use terminal zeros for 
(1.0) doses expressed in whole 
numbers. 




0.5 mg IIMisread as 5 mg. I Always use zero before a 




MEC Approval for Expanded Role of Registered Dietitians 
The following recommendations by the Therapeutics Committee for the Expanded Role of Registered 
Dietitians have been approved by the MEC. 
I. Registered Dietitians Taking Verbal Orders- MEC approval 9/4/01 
Registered Dietitians may take verbal orders from physicians related to nutritional care and to 
document those orders in the patient record. 
Changes to the Rules and Regulations to conform to the recommendation are: 
C. Patient Care #2 
(a) Verbal Orders: 
(iv) Verbal orders shall be taken only by a professional nurse except that the following 
individuals may take verbal orders: .......... Registered Dietitians ............. each 
with respect to procedures they are authorized to perform. 
(b) Telephone Orders: 
(iii) Telephone orders shall be taken only by a professional nurse except that the following may 
take telephone orders: ........... Registered Dietitians ............ with respect to procedures they 
are authorized to perform. 
II. Expanded Role of Registered Dietitians- MEC approvall2/4/0l 
1. May provide discharge diet education to patients different from current order 
(Example: post-op patient currently on Clear Liquids being given discharge diet education 
for low residue diet for when he goes home) 
2. May adjust diet orders, based on RD assessment, without obtaining physicians's order 
(Example: current diet order for Regular diet, but patient doesn't have dentures; RD adjust 
to mechanical soft diet) 
3. Certified Nutrition Support Registered Dietitian may adjust tube feeding rates and products 
(Therapeutic Substitution) without physicians orders. 
Therapeutic Substitution is an approved practice throughout the organization. It is well documented that 
timely nutrition intervention is crucial to positive patient outcomes and reduced length of stay. The 
American Society for Parenteral and Enteral Nutrition Standards of Practice for Nutrition Support 
Dietitians states: "[Nutrition Support Dietitians] may recommend, write orders, or obtain verbal orders 
for enteral and parenteral formulations (as guided by professional licensure or delineated by clinical 
privileges of an institution)". The Joint Commission on Accreditation of Health care Organizations 
Standards, standard TX.4.2 states, "Food and nutrition products are administered only on the 
prescription or order of a medical staff member or another individual who has been granted clinical 
privileges to write such prescriptions or orders." Therefore, clinical privileges as stated above is 
permissible. 
The clinical privileges outlined above will enable the provision of timely Medical Nutrition Therapy 
(MNT) significantly reducing the drain on Dietitian, Nursing, and Physician time in receiving orders to 
initiate routine nutrition care plans. This time will better be spent on direct patient care and more 
effective communication discussing a patients's medical condition, treatment plan, and progress with the 
patient care team. The entire clinical nutrition team at L VHN is dedicated in providing the highest 
quality MNT in support of our physicians and patients. We appreciate your continued support. 
The Last Word ... 
Tips and Techniques for the LastwordTM User 
February, 2002- Volume I, Issue 4 
CAPOE: What's it all About? 
by Carolyn K. Suess, R.N. 
Over the past year the term CAPO£ has 
been heard throughout the corridors of 
Lehigh Valley Hospital. Computer 
Assisted Physician Order Entry has 
certainly created a lot of excitement, as 
well as some confusion as to 
expectations of physicians. To help 
alleviate any feelings of uncertainty, it is 
important to communicate expectations 
to those that will receive CAPOE 
training in the near future, and at the 
same time dispel some myths. 
Myth #1 : I have to be a computer 
expert to master CAPOE 
Anyone newly introduced to CAPOE is 
not expected to be a computer expert. 
The system is intuitive by design and 
typing is kept to a minimum. The 
greatest challenge is time. The CAPO£ 
Order Pad arranges orders in a logical 
fashion by ordering department, and the 
more time spent using CAPOE the easier 
it becomes to find orders in the system. 
Additionally, multiple orders that are 
commonly placed at the same time (such 
as admission orders) are grouped into 
CAPOE Order Sets. Order sets alleviate 
the need to search for orders individually 
in the system. 
You will be notified through your 
chairman when you are expected to 
begin using CAPOE. An appointment 
for training with a Physician Software 
Educator will be arranged through your 
office manager. 
One-on-one training is conducted 
privately, to avoid distractions, and is 
"hands-on." A minimum of two hours of 
training time is required to learn the 
CAPOE system. However, if additional 
time is needed, the physician will be 
accommodated. Reference material, in 
the form of a user guide is provided to 
every physician trained in CAPOE. 
Myth #2: Once I'm trained, I'm on 
my own 
No one is ever left without a resource to 
fall back on. Problems and questions 
pertaining to CAPOE are addressed 
through the Helpdesk extension 8303, 
option #9. You will be prompted to 
enter your call back phone number, and 
the on-call trainer/analyst will return 
your call immediately. 
After a CAPOE unit activation, on-site 
user assistance is provided for the first 
few weeks by Physician Software 
Educators and I.S. Analysts. Following 
this period, Physician Software 
Educators round on a regular basis to 
provide additional assistance while 
physicians are on the unit. 
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Myth #3: If I don't have time to 
enter my orders, I can just give 
the nurse a verbal order 
Although this may sound reasonable, the 
expectation is for physicians to enter 
their own orders once they have been 
trained on CAPO E. Of course, there may 
be extenuating circumstances. If you are 
experiencing difficulty finding or 
placing an order, it is important to 
contact the Helpdesk immediately (ext. 
8303, option #9). 
Myth #4: I won't need to look up 
patient labs and vital signs on-line 
because the nurse will print them 
and place them on the chart 
For units that have implemented 
electronic entry of vital signs and 
medication administration as a prelude 
to CAPOE, the expectation is for 
physicians (both CAPOE and non-
CAPO E) to view them on-line. Nursing 
staff will not print reports and place 
them on the chart, since more accurate 
and timely information is available in the 
Lastword system. 
Patient information can be viewed not 
only on the unit where the patient is 
bedded, but anywhere in the hospital. 
For more information on viewing vital 
signs on-line, see the next article in this 
issue titled, Expect Improvements to 
Lastword Chart Tabs. 
Myth #5: There are never any 
wireless devices available for use 
Each CAPOE active unit should have 
several PenCentra hand-held devices 
available exclusively for physician use. 
Two devices reside in both physician 
dictation areas. If wireless devices are 
2 
not available or if they are not working 
properly, please contact the Helpdesk for 
assistance, or page a Physician Software 
Educator directly. 
Myth #6: I have to be on the 
patient's unit to enter my orders 
This is not true. CAPOE orders can be 
entered from any Lastword workstation 
and may also be entered remotely, from 
the physician's office. This is 
particularly convenient when admitting a 
patient to the hospital directly from the 
physician office. 
As we know, change is inevitable and 
CAPOE is bringing significant positive 
changes to Lehigh Valley Hospital. The 
Physician Software Educators on staff 
are here to smooth the transition to 
computer order entry, and you are 
encouraged to contact them with any 
training issues you may have: 
Lynn Corcoran-Stamm- ext. 1425 
Kimberlee Szep, R.N.- ext. 1431 
Carolyn K. Suess, R.N.- ext. 1416 
If you have training needs that pertain 
only to the Lastword system, please call 
ext. 1703. Arrangements can be made 
for training at your convenience. 
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Expect Improvements to 
Lastword Chart Tabs 
by Carolyn K. Suess, R.N. 
A New Year has arrived and so have 
new improvements to the chart tabs in 
the Physician Base screen in Lastword. 
The most significant difference you may 
notice is with the Viewer chart tab. The 
menu is more descriptive, allowing the 
user to better distinguish between the 
available views (see Figure 1 ). 
The views on the chart tab menu are as 
follows: 
VIEW ALL -This view displays 
Flowsheet Charted Results* (vital signs, 
height/weight, 110), Laboratory results, 
and Microbiology results. Values display 
for the past seven days and at four-hour 
intervals by default. 
New Viewer 
chart tab menu 
Vital Signs and I/0 - This view 
displays only vital signs and 
intake/output values*. Values display for 
the past seven days at eight-hour 
intervals by default. 
Intake and Output- This view 
displays only intake/output values*. 
Values display for the past seven days at 
24-hour intervals. 
LABS/MICRO- This view displays 
only Laboratory and Microbiology 
results. Values display for the past sev~n 
days and at four-hour intervals by 
default. 
Definition Screen - This selection 
displays the View Definition screen, 
offering the ability to select and 
customize views. 
*This data is only available on patient care units that utilize 
electronic entry of vital signs and medication administration. 
Figure 1 -Viewer chart tab displaying new menu selections 
3 
Page 31 
The second change impacts the Pt 
Care/Chart tab. Typically, only nursing 
should use this chart tab to enter vital 
signs and patient data. But due to its 
name, it sometimes confuses users who 
seek patient vital signs. Therefore, the 
menu was changed and a link to the 
Viewer was added to assist providers in 
finding vital signs for their patients (see 
Figure 2). 
To view patient vital signs from the Pt 
Care/Chart tab, after selecting a patient 
click on the tab to display the menu, then 
click on the Vital Signs - PHYSICIAN 
selection. The Viewer opens and displays 




Pt Care/Chart menu 
with link to Viewer 
To learn more about the Viewer and 
other Lastword features, please take a 
moment to review the on-line 
documentation for Lastword. Both the 
CAPOE and Non-CAPOE Physician 
User Guides can be found on the 
L VHNN Intranet under the Resources 
heading Lastword for Physicians. 
If you wish to obtain a paper copy of 
either document, or are interested in a 
personal training session, please contact 
one of the Physician Software Educators 
on staff: 
Lynn Corcoran-Stamm - ext.1425 
Kimberlee Szep, R.N. - ext. 1431 
Carolyn K. Suess, R.N. - ext.1416 
Lynn, Kimberlee and Carolyn will be 
pleased to assist you. 





NEWS FROM THE LIBRARY 
OVID Instruction. 
Contact Barb Iobst at 61 0-402-S40S to arrange for instruction 
in the use of OVID's MEDLINE and its other databases. 
After-Hours Access to L VH-MUHLENBERG Library. 
Recently, the L VH-Muhlenberg library door was converted to 
a card-access area for the convenience of our patrons. You 
can now gain entrance to the Library by running your hospital 
I.D. through the card reader outside the door. If your card 
does not open the library door, please email Barbara Iobst 
with your name and social security number. 
Recently Acquired Publications. 
Library at 17th and Chew Streets 
"Innovations in End-of-Life Care: Practical Strategies and 
International Perspectives, " 2000 
"Innovations in End-of-Life Care" Vol. 2, 2001 
Library at CC & I-78 Campus 
"Occupational Medicine: State of the Art Reviews." 
(Subject: "Health Hazards in the Arts" 
December, 2001 -Volume 16, No.4 
"Facial Plastic Surgery Clinics of North America." 
(Subject: "Vascular Birthmarks o[the Head and Neck" 
November, 2001- Volume 9, No.4 
Library at L VH-Muhlenberg 
"Surgical Clinics of North America" 
(Subject: "Vascular Trauma: Complex and Challenging 
Injuries" Part I) 
December, 2001- Volume Sl, No.6 
L VH-Muhlenberg and Library 17 
"Dental Clinics o[North America. " 
(Subject: "Evidence-Based Dentistry" 
January, 2002- Volume 46, No.1 
Future Educational Activity 
Next EPEC conference will be on Thursday, March 14'h 
and Friday, March 15th in the School of Nursing? 
1 
Computer-Based Training (CBT): 
Computer Based Training (CBT) programs are available for 
L VHHN staff. Topics covered by the CBT programs include: 
Access 2.0 Power-Point 4.0 
Windows NT 4 Word 97 
Excel 97 Access 97 
PowerPoint 97 Lotus 1-2-3 Millennium 
WordPerfect S E-mail GUI 
PHAMIS LastW ord Inquiry Only commands 
CBT programs replace the instructor-led classes previously 
held at Lehigh Valley Hospital. A proctor will be in the room 
with the learner while he/she takes the CBT, but the learner 
will control the pace and objectives of the learning. 
Computer Based Training takes place in Suite 401 of the 
John & Dorothy Morgan Cancer Center (the computer 
training room) and in the Muhlenberg Hospital Center 
computer training room (off the front lobby). The schedule 
of upcoming dates is as follows: 
CBT sessions for JDMCC, suite 401 are as follows: 
February 12, noon- 4pm 
March 26, Sam - noon 
April23, Sam- noon 
Sessions at MHC, I.S. Training room are as follows: 
March 5, noon- 4pm 
May 14, noon- 4pm 
Twelve slots are available for each session. 
To register, please contact Suzanne Rice via e-mail or at 610-
402-2475 with the following: 
date of session 
second date choice 
department 
phone number 
You will receive an e-mail confirming your choice within two 
business days. If you have any questions, please contact Craig 
Koller at 610-402-2413 or through e-mail. 
Any questions, concerns or comments on articles from CEDS, please contact 


















7am Family Practice GR-JDMCC 
IA/B 
7am Surgical GR CC-Aud 
Sam Pediatric GR CC-Aud 
12 noon Medical GR CC-Aud 
12 
7am Surgical GR CC-Aud 
Sam Pediatric GR CC-Aud 
12 noon Medical GR CC-Aud 
19 
7am Surgical GR CC-Aud 
Sam Pediatric GR CC-Aud 
12 noon Medical GR CC-Aud 
26 
7am Surgical GR CC-Aud 
Sam Pediatric GR CC-Aud 
12 noon Medical GR CC-Aud 
Wed 
6 
12 noon MHC TB OR Con 
Rm 
13 
12 noon Pulmonary TB 
JDMCCCRI 
12 noon MHC TB OR Con 
Rm 
20 
12 noon MHC TB OR Con 
Rm 
27 




Sam Emergency Medicine 
GR Banko Rm 1&2 
12 noon Combined TB 
JDMCCCRI 
14 
Sam Emergency Medicine 
GR 4'h Fl Conf. Rm 
12 noon Combined TB 
JDMCCCRI 
21 
Sam Emergency Medicine 
GR 4'h Fl ConfRm 
12 noon G.I.TB JDMCC 
CRI 
28 
7:30am Trauma 2002 
Conference Holiday Inn 
Sam Emergency Medicine 
GR 4'h Fl Con. Rm 




7am GYN GR CC CRI 
II am Neurology Conf CC Cr I 
12 noon Breast TB JDMCC CR I 
8 
?am OBGYN GR CC CRI 
II am Neurology Con fCC Crl 
12 noon Breast TB JDMCC CR I 
15 
7am OBGYN GR CC CRI 
II am Neurology ConfCC Crl 
12 noon Breast TB JDMCC CR I 
22 
7am OBGYN GR CC CRI 
II am Neurology Conf CC Cr I 













RECOMMENDATIONS TO THE BOARD OF TRUSTEES 
FROM THE GENERAL MEDICAL STAFF 
FOR REVISIONS TO THE MEDICAL STAFF BYLAWS 
FROM MEETING OF DECEMBER 10, 2001 
The following proposed revisions, having received the recommendation of the Bylaws Committee, the 
Medical Executive Committee, and the General Medical Staff, are being presented for action. 
Registered Dieticians Taking Verbal Orders -A recommendation by the Therapeutics Committee to the 
Medical Executive Committee requesting that Registered Dieticians be able to take verbal orders from 
physicians related to nutritional care and to document those orders in the patient record was approved at 
the 9/4/01 Medical Executive Committee. The corresponding proposed changes to the Rules and 
Regulations follow: 
C. PATIENT CARE #2: 
(a) Verbal Orders: 
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(iv) Verbal orders shall be taken only by -a prefessieaal regis~erea &llfse Registered Nurses and e!isep~ ~at 
tlie fellewiag iaah~a1:1als Hl&y ~ie ·~eRial eraers: jqas"~ieaers, Licensed Practical Nurses, Respiratory 
Therapy Technicians, Physical Therapy Technicians, Pharmacists, Registered Dieticians. and 
Paramedics practicing under PA Code 117.30 (relating to emergency paramedic services) each with 
respect to procedures they are authorized to perform. 
(b) Telephone Orders: 
(v) In the Emergency Department, verbal orders may only be given to a Registered Nurse. 
(i) . Telephone orders must be signed within twenty-four (24) hours. 
(ii) A member of the Medical Stilff may, but is not required to, sign the order of another member 
of the Medical Staff. A resident physician may sign for another resident physician on his or 
her same PGY level or below. 
(iii) Telephone orders shall be taken only by -a prefessieaal regis~erea &llfse Registered Nurses and 
eliSef:!~ ~kat ~e fellewiag may ~e ~elepkeae eraers: Respiratory Therapy Technicians, 
Physical Therapy Technicians, aae Pharmacists, and Registered Dieticians. aae with respect to 
procedures they are authorized to perform. 
Certified Registered Nurse Practitioners -In November, 2000 the State Board of Medicine and the State 
Board of Nursing have promulgated regulations, which permit qualified Pennsylvania CRNPs to prescribe 
and dispense drugs. With this change, the attached changes are being proposed to the Rules and 
Regulations: 
C. PATIENT CARE #3: 
3. Orders shall be written only by physicians, dentists, oral surgeons, podiatrists, certified registered nurse 
practitioners. and physician assistants acting within the scope of their respective licenses and authorized according 
to Medical Staff Bylaws and these Rules and Regulations. Orders may only be written by a physician extender 
under the following circumstances: 
(i) The physician employs a physician extender whom he or she directly supervises and for whom 
he or she has responsibility. 
(ii) The physician extender has been approved and credentialed pursuant to these Bylaws and by 
the Governing Body for such duties. 
Recommendations to the Board of Trustees 
From the General Medical Staff 
Meeting of December 10, 2001 
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(iii) Except as specifically noted below, no medication orders may be written by any physician extender unless such order is 
written in the presence of and immediately countersigned by the supervising physician. Hewever, 'Nftefe a eeRiHeEI paysieiaa assislaRt 
aas aeeH speeiHeally ereEieBtialeEI aBEl appreYeEI ay tae GeYeFHiHg SeEly te preseriae FBeEiieatieHS, SI!Sft erEier. FBI!St ae EleeYFBeHteEI WfteH 
rel~·eEI aaEI FBYst ae eeYHtersigaeEI ay tae sYper'>'isiag paysieiaa ·ritftiH 72 aeYFs. The following apply to medication orders written by 
physician extenders who are specifically credentialed and approved by the Governing Body to prescribe medications: 
a. Certified registered nurse practitioners - Countersignature by the collaborative 
physician is not required. 
b. Certified physician assistants -The order must be documented when relayed and 
must be countersigned by the supervising physician within 72 hours. 
(iv) Certified physician assistants may write routine diagnostic, diet, and activity orders as directed 
and countersigned by the supervising physician. 
(v) All medical student orders shall be countersigned by a licensed physician. 
(vi) Certified registered nurse practitioner orders do not require countersignature by their 
collaborative physician. 
17. Members of the Medical Staff, and appropriately credentialed certified registered nurse practitioners and physician 
assistants, are responsible for providing a complete medication order. All orders for medications or intravenous 
solutions should contain the drug nomenclature, strength, frequency of dosage, and route of administration, where 
applicable. With respect to intravenous solutions, the desired flow rate and/or volume should be included. Ordering 
medication by package size (e.g. one ampule, a vial, etc.) is considered an incomplete order and will require 
clarification by the Pharmacist. Certain combination injectable products do not contain clear quantitative 
descriptions and are exempt from this requirement. These include multi-vitamin injections and standard injectable 
multi-trace elements. 
18. Drugs shall be administered only upon· the proper order of a practitioner, appropriately credentialed certified 
registered nurse practitioner. or appropriately credentialed physician assistants, acting within the scope of his or her 
license and authorized according to these Medical Staff Bylaws and Rules and Regulations. Drugs shall be 
administered directly by a practitioner qualified according to Medical Staff Bylaws, Rules and Regulations, or by a 
certified registered nurse practitioner. er-ey a prefessieaal registered nurse or by a licensed practical nurse with 
pharmacy training. Graduate practical nurses, graduate nurses, and students in approved schools of nursing may be 
authorized to administer drugs, but only under the supervision of a registered prefessieaal nurse or a physician 
under 49 PA Code 21.14 (relating to the administration of drugs). 
19. Narcotics and other dangerous medications (as defined by the Pharmacy & Therapeutics Committee and/or Medical 
Executive Committee) that are ordered without time limitation of dosage shall be automatically discontinued after 
seventy-two (72) hours. Drugs shall not be discontinued without notifying the physician at least 48 hours before an 
order is automatically stopped. If the order expires after 12:00 a.m., it shall be called to the attention of the 
physician after 6:00 am. on the same day. Members of the Medical Staff, and appropriately credentialed certified 
registered nurse practitioners and physician assistants, shall make every effort to order only those drugs, or the 
generic equivalents, listed in the Facility's Formulary. Under special circumstances, drugs not listed in the 
Formulary, but necessary for the patient, will be obtained by the pharmacy. Any drugs so ordered, but not yet 
approved by the FDA, must be approved by the institution or Review Committee, prior to its administration. 
20. In order to prevent the continuation of antibiotics and steroids in dosages larger or periods of time longer than 
indicated, all new or rewritten orders for antibiotics and steroids, shall specify a time limit for administration of the 
drug. In the event that no limit is specified, the ordering member of the Medical Staff, or appropriately credentialed 
certified registered nurse practitioner or physician assistant, shall be contacted within twenty-four (24) hours to so 
specify. Unless otherwise specified, all antibiotic orders shall be instituted as STAT orders. 
Chiropractor Clinical Duties - Clinical duties have been approved by the Medical Executive Committee 
for Chiropractors which requires the following change to the Rules and Regulations: 
C. PATIENT CARE #3: 
3. Orders shall be written only by physicians, dentists, oral surgeons, podiatrists, certified registered nurse 
practitioners, chiropractors. and physician assistants acting within the scope of their respective licenses and 
authorized according to Medical Staff Bylaws and these Rules and Regulations. Orders may only be written by a 
physician extender under the following circumstances: 
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Deletion of New Procedure Committee - The recent approval of the Technology Assessment Committee 
eliminates the need for the New Procedure Committee as the T AC Committee is a more inclusive 
Committee for the acquisition and/or implementation of new technology or advances in existing 
technology. Recommendation was made to delete the New Procedure Committee: 
fl. !>levi' PreeeEiHres CeRlHlittee: 
(i) · Psmese: Te review ~e feasieili~· ef aaEI pelieies fer the i!Bfllemeamtiea ef ae•.v preeeEisres, 
teehHi!iHes aaEI treatmeat meEialities ia the Hespitals. A aew preeeEisre is a preeeEiHre, teehHi!iHe er 
treatmelilt J:Beeality that is IiSee iH the R9Sflital 91i1 a patielilt, eKSIHeiag researee Stlieies QflQ HeW 
EIRigs, tl:!at l:!as Bet eeea Eleae pre~·iessl;y at the applieaele Hespital. 
(ii) Dsties: 
A. Te meet at least !iliat'terly, er mere eftea whea eallee lifl9H e;y Departmeat ChaiFf!erseas 
er the MeEiieal eKeeHtive CeRlHlittee, fer the flliFfl9Se ef re¥iewiag aae reeemmeaEiiag 
iastitlitieaal pelie~· fer the implemeamtiea eflilew preeeEiHres, teehlili!iHes aaEI treatmeat 
meEialities. 
8. Te repert the results ef the Cei:BBlittee' s iavestigatieas iH the feFJ:B ef a reeeHUBeaeatiea 
te the Me&ieal eKeestive Cei:BBlittee iaelaSiHg a ee!Bfllete eeseriptiea ef the preeeEiHre, a 
fiaaneial aaalysis, aae reeeHUBeHEieEI ereeeatialiag eriteria fer ~e HeW preeedl:lre. 
(iii) Cemeesitiea: 
ChaiFf!ersea Me&ieal Staff Memeer 
Reeer&iag Seereta:Fj 
AEimiaistrati•Je SeF¥iees/Assistant te the Presieeat 
'Dfreeter, Safe~· 
'Dfreeter, Bie Me&ieal eagilleeriag 
Fiaaneial SeF¥iees FiBaaeial ,'\Halyst 
Risk Maaager 
(ti) Me&ieal Staff Memeers 
Rules and Regulations - E. Records - #20 - ("Housekeeping detail") - The following is a "housekeeping" 
issue to update the Rules and Regulations to conform to current administrative titles: 
20. Free access to all medical records of all patients shall be afforded to members of the Medical Staff in good standing 
for bona fide study. Any study must preserve the confidentiality of personal information concerning individual 
patients. Certain studies may fall within the category of peer review. As a result, all studies must have prior 
approval by: 
(a) an appropriate Audit Committee; or 
(b) Chairperson of the Department; or 
(c) the Seaier Viee PresideRt Chief Medical Officer fer Cliaieal SBF¥iees or Viee PresiEieat ef MeEiieal 
Affairs Senior Medical Director. 
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Information And Advice About Our Laboratory 
January 2, 2002 
Effective January 16, 2002, Health Network Laboratories (HNL) will implement a change in 
methodology for Troponin I and Creatine Phosphokinase Isoenzyme both of which are 
orderable separately and are included in a MI Profile. 
SPECIMEN REQUIREMENTS: 
• Troponin I 
• Creatine Phosphokinase Isoenzyme 
(Total CK and Mass CK-MB fraction) 
• MI Profile 
NEW ORDER CODES· . 
) 
one green top 
(lithium heparin) 
tube 
TEST OLD TEST CODE NEW TEST CODE 
MI Profile, Initial MIIN MIPIN 
MI Profile, #2 MI2 MIP2 
MI Profile, #3 MI3 MIP3 
Troponin I TROPN TROPI 
Creatine Phospho1inase Isoenzyme CKI CKIMB 
NEW REFERENCE RANGES· . 
OLD NEW OLD NEW 
Interpretation TROPONIN TROPONIN MCKMB MCKMB 
of Results Reference Reference Reference Reference 
Range Range Range Range 
Consistent with < 0.10 ng/mL <0.08ng/mL < 3.38 ng/mL < 2.37 ng/mL 
non-MI condition 




Please post this announcement to ensure compliance onjanuary 16. 2002. 
If you have any questions, please contact Dolores Benner at 610-402-8177 or our Customer Care Call 
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